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     Abstract 
Integrin β1 is essential for pancreatic beta-cell development and maintenance throughout life 
in rodents and human fetal islets. However, the effects of a postnatal β1 integrin knockout 
(β1KO) specific to pancreatic beta-cells of mice is undetermined. We generated mice with 
CreERT recombinase specific to the mouse insulin promoter (MIP), allowing us to induce a 
β1KO upon injection of tamoxifen (MIPβ1KO model). 
At 3-4 weeks of age tamoxifen was injected and mice were sacrificed at 8 (male) and 16 
weeks (female) post-tamoxifen. MIPβ1KO mice had impaired glucose tolerance, reduced 
beta-cell mass and islet density. The impairment in glucose tolerance remained in aged mice. 
Male MIPβ1KO mice also had impaired insulin expression and secretion, along with reduced 
Pdx-1, p-FAK, p-ERK, and p-Akt protein levels. Insulin exocytosis proteins were also 
reduced in male MIPβ1KO mice. These findings demonstrate a significant role for β1 
integrin in the survival and function of adult murine beta-cells. 
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1 Chapter 1 - Introduction 
1.1 Significance of the study 
The most promising avenue for the treatment of diabetes is transplantation of pancreatic 
islets, yet an inadequate donor supply and short-term survival of transplanted islets are 
limiting factors. Finding optimal conditions for isolation of islets, transplantation, and 
generation of functional beta-like cells from stem cells is of critical importance to 
circumvent these issues. The loss of β1 integrin, a protein critical in cell-extracellular 
matrix (ECM) interactions, has not been studied in beta-cells of adult mice. Further 
understanding of the relationship of the ECM and postnatal beta-cells in their native 
environment will help us understand the ideal way to handle beta-cells in therapeutic 
conditions.  
1.2 The pancreas and its development 
The pancreas is a glandular organ that can be divided into two morphologically distinct 
regions: the exocrine and endocrine pancreas. The exocrine tissue comprises 97% of the 
pancreas and consists of the acinar cells which secrete a variety of digestive enzymes 
(proteases, lipases, and amylase) and the ductal system, responsible for transporting 
enzyme secretions into the duodenum. The remaining 3% of the pancreas are the highly 
vascularized pancreatic islets of Langerhans which were first discovered by Paul 
Langerhans in 1869 during his PhD studies (Langerhans, 1869). Islets are dense clusters 
of 5 different hormone secreting cell types (alpha-cells, beta-cells, delta-cells, gamma-
cells, and epsilon-cells), that secrete the hormones glucagon, insulin, somatostatin, 
pancreatic polypeptide, and ghrelin respectively. Islet architecture varies between 
frequently studied mammalian species, with different cellular compositions in porcine, 
canine, murine, and human islets (Kim et al. 2009, Wang et al. 1999). Murine islets 
consist of a beta-cell rich core that comprises ~87% of the islet, surrounded by an outer 
layer of alpha-cells (7% of the islet), with the remaining cell types making up the 
remaining 6% (Rothers & Harlan 2004). However, human islets contain a higher 
percentage of alpha-cells (36%), with beta-cells accounting for 54% of the islet (Rothers 
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& Harlan 2004). Regulation of glucose metabolism is a highly intricate process carried 
out through the release of glucagon and insulin. In response to hypoglycemia (low blood 
glucose), glucagon is released from alpha-cells and stimulates glucose production from 
the liver through conversion of glycogen into glucose. Alternatively, insulin is secreted 
by beta-cells after a meal or in hyperglycemic conditions (high blood glucose), which 
binds to the insulin receptor found on peripheral cells such as those in the liver, muscle, 
and adipose, which uptake and store excess glucose. 
The pancreas is derived from an outgrowth of endodermal epithelium in the foregut that 
expresses Sry-related HMG box 17 protein (Sox17) (Tateishi et al. 2008). The primary 
transition of pancreatic development begins on mouse embryonic (e) day 8.5, where the 
outgrowth begins to divided into two buds known as the dorsal and ventral buds that 
express key transcription factors pancreatic duodenal homeobox 1 (Pdx-1) and pancreatic 
transcription factor 1a (Ptf1a) (Offield et al. 1996, Kagawauchi et al. 2002, Krapp et al. 
1996, Hald et al. 2008. Meulen & Huising, 2015). The pancreatic buds fuse at the 
beginning of the secondary transition of pancreatic development (e12.5-e18.5) and forms 
one cohesive organ with a definitive tip region (cells destined for an exocrine cell fate 
expressing Ptf1a) and interior trunk region (cells destined to become either endocrine or 
ductal cells expressing NK6 homeobox 1 (Nkx6.1)) that is dependent on high levels of 
Notch activity (Afelik & Jensen 2012, Afelik et al. 2012). Most tip cells have fully 
differentiated into acinar cells by e15.5 (Pan et al. 2013). Within the trunk, high levels of 
Notch activity result in activation of hairy and enhancer of split-1 (Hes1), an inhibitor of 
Neurogenin 3 (Ngn3). However, lowered levels of Notch leads to a loss of Hes1 with 
continued activation of Sox9, an activator of Ngn3, and these cells migrate away from the 
ducts to commit to an endocrine cell fate (Shih et al. 2012). Endocrine cells further 
differentiate into the five aforementioned cell types, and it is the expression of Pdx-1, 
Nkx6.1 and paired box 4 (Pax4) that lead to a beta-cell fate (Collombat et al. 2003, 
Gannon et al. 2008, Henseleit et al. 2005, Holland et al. 2002, Shih et al. 2013, Sosa-
Pineda et al. 1997). Endocrine cells begin to cluster into islet-like structures around e16 
(Shih et al. 2013, Habener et al. 2005). The tertiary period of pancreatic development 
(e19.5 – post natal day (p) 21), is a period of remodelling where beta-cell neogenesis, 
proliferation and apoptosis occurs, leading to the final pancreatic structure observed in 
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adults (Kaung 1994, Scaglia et al. 1997). By postnatal day 21, the islets are fully mature 
and beta-cells are capable of maintaining normoglycemia through secretion of insulin 
into the plasma in response to increased blood glucose levels.  
1.3 Beta-cells and Insulin Secretion 
Glucose-stimulated insulin secretion is a tightly regulated process beginning with up-take 
of glucose by pancreatic beta-cells via the glucose transporter type 2 (Glut2) protein in 
rodents. Intracellular glucose leads to increased production of ATP, and an increase in the 
ATP/ADP ratio leading to closing of voltage-gated potassium channels, initiating 
depolarization of the cell (Ashcroft et al. 1984). This causes an influx of Ca2+ into the cell 
via L-type Ca2+ channels (Hoenig & Sharp 1986, Straub & Sharp 2002, Wollheim & 
Sharp 1981) and results in docking of insulin containing granules to the plasma 
membrane with the aid of soluble N-ethylmaleimide-sensitive attachment protein 
receptors (SNAREs), tethering proteins such as Rab (Ungar & Hughson 2003), and 
microtubule remodelling (Kalwat & Thurmond 2013). Insulin exocytosis is a biphasic 
phenomenon. The first phase of insulin release begins approximately 1-2 minutes after 
glucose is ingested. Insulin release plateaus 3-4 minutes after glucose ingestion and 
declines rapidly until 8 minutes afterwards as part of the KATP-dependent (triggering) 
pathway (Straub & Sharp 2002). This initial phase releases insulin from an immediately 
available pool of insulin granules (known as the readily releasable pool), which are pre-
docked insulin granules on the cell membrane (Straub & Sharp 2002, Wang & Thurmond 
2009).  The second phase of insulin release begins after the first, with an increasing 
release of insulin into the plasma that peaks at 25-30 minutes post glucose intake and this 
is referred to as the KATP-independent (augmenting) pathway (Straub & Sharp 2002). 
During the second phase of insulin release, insulin exocytosis occurs from a pool of 
insulin granules known as the storage granule pool and the release of these granules can 
be influenced by acetylcholine and glucagon like peptide-1 (GLP-1), which lead to 
increased levels of diacylglycerol (DAG) and cyclic adenosine monophosphate (cyclic 
AMP) respectively (Straub & Sharp 2002, Wang & Thurmond 2009). Once in 
circulation, insulin interacts with the insulin receptor found on multiple peripheral cell 
types (such as liver, fat, muscle and beta-cells) and leads to the phosphorylation of insulin 
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receptor substrates (IRS). Phosphorylated IRS subsequently interacts with signalling 
pathways (e.g. phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene 
(Akt) and mitogen activated protein kinase (MAPK)/ extracellular signal-related kinse 
(ERK)) that control cell metabolism, differentiation, and proliferation (Giancotti & Guo 
2004). Within the beta-cell, the binding of insulin to the insulin receptor plays a positive 
autocrine role that regulates subsequent insulin secretion (Leibiger et al. 2001). When 
insulin binds to insulin receptor type A expressed on the beta-cell surface, PI3K class Ia 
and ribosomal protein S6 kinase beta-1 (p70s6k) are upregulated leading to enhanced 
insulin gene transcription (Leibiger et al. 2001). The implications of insulin and its 
downstream signalling are vast and vary between cell types, and the topic is beyond the 
scope of this thesis, however, the way by which insulin exocytosis takes place is worthy 
of examination. 
Exocytosis is mediated by SNARE proteins, which work in a coordinated fashion. In 
general, a SNARE protein consists of a conserved 60-70 amino acid heptad repeat (the 
SNARE motif) with a transmembrane domain in the C-terminus and independently 
folded domains at the N-terminus (Weimbs et al. 1997, Jahn & Scheller 2006). SNAREs 
can be loosely defined as either target-SNAREs (t-SNAREs) which reside on the plasma 
membrane, or vesicle-SNARES (v-SNAREs) which are present on vesicles (Jahn & 
Scheller 2006).  The formation of SNARE complexes varies between organism and tissue 
types (Kasai et al. 2012). Studies of insulin exocytosis in beta-cells of rats and the rat cell 
lines HIT-T15, βTC6-F7, and RIN1056A, have shown that protein components of t-
SNARES syntaxins (1-4) and synaptosome associated protein 25 (SNAP-25), and that of 
v-SNAREs vesicle associated membrane protein-2 (VAMP-2) and synaptotagmin III are 
expressed (Wheeler et al. 1996). Among the syntaxin family of proteins, syntaxin1A and 
syntaxin3 have been shown to be key mediators of insulin exocytosis. A Cre-mediated 
beta-cell specific knockout of syntaxin1A in mice lead to impaired first and second phase 
insulin secretion (Liang et al. 2017). Syntaxin3 siRNA in INS-1 cells and isolated mouse 
islets (3-6 months old) lead to a reduction in new comer insulin granules, whereas 
overexpression of synaxin3 enhanced both phases of insulin exocytosis (Zhu et al. 2013). 
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A general schematic illustrating the function of SNAREs is presented (Figure 1.1) t-
SNAREs and v-SNAREs from a four-helix structure at the site of exocytosis and is 
dissociated by N-ethylmaleimide-sensitive factor (NSF) after exocytosis is complete 
(Jahn & Scheller 2006).  The formation of this four-helix structure is due to the 
contribution of helixes by individual proteins in the complex: SNAP-25 contributes two 
helixes, while syntaxin1A and VAMP2 each contribute one helix, allowing for membrane 
fusion and exocytosis (Fasshauer 2002).  
Beyond the core components mentioned above, there are a multitude of other factors that 
are responsible for the regulation of exocytosis, two of which are Mammalian unc18 
(Munc18) and synaptotagmin III.  Munc18 has three known isoforms, Munc18a, 
Munc18b, and Munc18c (Tellam et al. 1995). Munc18a shares exact homology with 
Munc18, whereas Munc18b has 61% homology, and Munc18c has 51% (Tellam et al. 
1995). Studies have shown that Munc18a and Munc18b have highest affinity towards 
syntaxins 1-3, whereas Munc18c affinity for binding is preferential to syntaxin 4 (Oh & 
Thurmond 2009). Studies have best characterized the relationship between Munc18 and 
syntaxin1A, demonstrating that Munc18 regulates Syntaxin1A by maintaining it in a 
closed confirmation, preventing formation of the SNARE complex by inhibiting 
interactions with VAMP2 and that these interactions are highly dependent on a 1:1 
syntaxin:Munc18 molar ratio, and this seems to hold true for all Munc18 and syntaxin 
proteins (Reviewed in Thurmond 2013). Since insulin exocytosis is Ca2+ mediated, it is 
intuitive to think that part of the SNARE complex would sense calcium, and 
synaptotagmin III plays this role (Brown et al. 2000, Wheeler et al. 1996). Synaptotagmin 
III is found within secretory vesicles along with insulin, and its cytoplasmic Ca2+ sensing 
region leads to a conformational change upon influx of Ca2+ into the cell, allowing its 
interaction with syntaxin and SNAP25 on the plasma membrane (Brown et al. 2000). 
Impairment of insulin secretion and/or the signalling pathways at one or multiple areas 
leads to the development of diabetes mellitus (DM). There are several forms of DM with 
different treatment options available depending on the pathology of the disease.  
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Figure 1.1 SNARE mediated insulin exocytosis in beta-cells 
A) In normal conditions the helices contributed by syntaxin1A (Stx1A), SNAP25, and 
VAMP-2 remain apart and Munc18a maintains Stx1A in a closed conformation. B) 
Influx of calcium (Ca2+) into the cell results in the open conformation of Stx1A through 
release of inhibition by Munc18, which now aids in stabilizing the SNARE complex at 
the plasma membrane. At this time, the helices from Stx1A, SNAP25, and VAMP-2 
come together and result in fusion of the vesicle with the plasma membrane and 
subsequent insulin exocytosis. 
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1.4 Diabetes mellitus 
DM is diagnosed as one of two types based on the pathology of the disease. Type 1 
diabetes (T1D) is the result of autoimmune destruction of the pancreatic beta-cells, 
leading to insufficient insulin production. In T1D, individuals develop severe 
hyperglycemia unless exogenous insulin is administered. In contrast, the development of 
type 2 diabetes (T2D) is multi-factorial, ranging from inefficient beta-cell mass to 
reduced sensitivity to insulin in peripheral tissues. T2D also results in hyperglycemia, but 
less severe cases can be treated with modifications in diet and increased physical activity. 
Medications often come in one of two forms: those that aid in maintaining sufficient beta-
cell function, such as glucagon-like peptide 1 (GLP1) agonists or DPP4 inhibitors 
(Lamber et al. 2003, Versophl et al. 2009), or medications like metformin that target 
peripheral tissues to increase glucose uptake (e.g. muscle (Bailey & Puah 1986, Rosetti et 
al. 1990, Galsuka et al. 1994) and fat (Cigolini et al. 1984)) or decrease glucose 
production (e.g. liver) (Bailey & Wollen 1988, Bailey 1992, Bailey 1993). A promising 
avenue for the treatment for T1D is the restoration of functioning beta-cells in diabetic 
patients using islet transplantations. The Edmonton protocol, established during the 1990s 
and still in effect today, involves isolating islets from human cadaveric donors and 
transplanting them in the hepatic portal vein of transplant recipients (Shapiro et al. 2000). 
However, islet transplantation currently has many shortcomings that limit the long-term 
production of endogenous insulin. Transplant recipients must balance taking 
immunosuppressant drugs to prevent rejection while avoiding beta-cell toxicity (Zeng et 
al. 1993). In addition, cells are often damaged during the isolation process leading to 
impaired integrin and ECM interactions, induced cell death and reduced cell function, 
and a shortage of donor tissue, leading to inadequate beta-cell mass over time (Shapiro et 
al. 2000, Ryan et al. 2005). To circumvent these issues, designing optimal culture 
conditions for maintaining islet architecture and transplant environments for donor tissue 
and/or beta-like cells derived from stem cells is essential. One way to do this is to study 
how the integrin family of receptors, essential in cellular adhesion, interacts with the 
surrounding extracellular matrix (ECM) to maintain islet integrity, beta-cell function and 
survival.  
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1.5 Integrin receptors and the ECM 
Integrins are heterodimeric proteins consisting of α and β subunits (18 α and 8 β subunits 
in mammals) that combine to form 24 different combinations (Takada et al. 2007, 
Barczyk et al. 2010). The ligands for integrins are proteins that comprise the extracellular 
matrix (ECM). The ECM consists of negatively charged glycosaminoglycans that form a 
porous, yet hydrated, gel-like substance in which a variety of proteins such as collagens, 
fibronectin, laminins, and vitronectin reside. These proteins provide stability and support 
for cells, while at the same time having profound influence on cell differentiation, 
function, proliferation, and survival (Aszódi et al. 2006, Streuli 1999, Rosso et al. 2004, 
Kleinmen et al. 2003). The ability of the ECM to influence the fate of cells is ultimately 
dependent on a variety of adhesion molecules that act to govern interactions with the 
environment around them. Cell adhesion molecules can be broadly defined into one of 
four categories: Immunoglobulin superfamily cell adhesion molecules (IGSF CAMs), 
integrins, cadherins, and selectins. Although there is a multitude of resources providing 
in-depth information on the different types of cell adhesion molecules, integrin-ECM 
interactions are the focus of this thesis.  
 
Integrins can be divided into four general classes based on the extracellular ligands they 
bind to as dictated by the α-subunit that governs ligand binding specificity (Figure 1.2): 
arginine-glycine-aspartic acid (RGD) receptors (e.g., fibronectin and vitronectin), 
GFOGER receptors (collagens), leukocyte-specific receptors, and laminin receptors 
combinations (Takada et al. 2007, Barczyk et al. 2010). Integrins exist in an inactive 
conformation with low affinity for binding to their ligands (Springer & Dustin 2012). 
Inside-out signalling is a process by which integrins become activated into a high affinity 
ligand binding state, and talin binding to the cytoplasmic tail of the β-integrin subunit has 
been implicated as the key protein required for the conformational change (reviewed in 
Wang 2012). The binding of talin makes a direct connection between an integrin, the 
ECM, and the actin cytoskeleton. The kindlin family of focal adhesion proteins has been 
shown to activate integrins, with loss of integrin activation seen in kindlin inhibition 
studies (Kloeker et al. 2004, Harburger & Calderwood 2009). After the initial binding of 
talin and kindlins, the now activated integrin will bind to extracellular ligands leading to 
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outside-in signalling and resulting in further scaffolding of signalling proteins within the 
cell into groupings known as focal adhesions. Focal adhesions, mediated by focal 
adhesion kinase (FAK), can lead to a variety of downstream signalling processes 
involving the activation of RhoGTPases, serine/threonine kinases, and tyrosine kinases 
such as ERK1/2 as well as Akt (Danen & Sonneberg 2003). The multitude of proteins 
that coalesce together during outside-in signalling is vast and reviewed in Harburger & 
Calderwood (2009), but a more detailed description of β1 integrin-FAK related signalling 
is discussed in section 1.8.  
 
β1 integrin is the most abundant β-integrin subunit and is expressed ubiquitously. β1 
integrin associates with 12 different α subunits (α1-α11 and αv) (Barczyk et al. 2010). 
Signalling through β1 integrin is dependent on the cytoplasmic domain, in which a NPxY 
motif is present and leads to inside-out activation of β1 (Cordes et al. 2006) and outside-
in activation of FAK (Wennerberg et al. 2000). β1 integrin through its affinity with 12 
different α subunits, binds to all major categories of ECM proteins and is involved in 
actin remodelling, cell polarity, movement, and induction and maintenance of cellular 
differentiation and function (Brakebusch & Fassler, 2005); including cartilage and bone 
formation (Aszódi et al. 2006), skeletal muscle development (Burkin et al. 2001, 
Schwander et al. 2003), epidermis formation (Brakebusch et al. 2000), development of 
the cerebral cortex (Belvindrah et al. 2007), and angiogenesis (Mettouchi & Meneguzzi 
2006). Researchers have begun to uncover the role of β1 integrin in the pancreas, 
specifically with regard to islet development, function and survival, but substantial work 
remains to be done. 
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Figure 1.2 The association of α and β integrins and their ligands 
The formation of potential αβ integrin heterodimers is highlighted along with their 
preferred ligands. As indicated, β1 integrin associates with 12 different α integrins 
allowing it to bind to all four major types of extracellular ligands (collagens, laminins, 
RGD motif containing proteins such as fibronectin, and leukocytes). 
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1.6 β1 integrin and islet development 
Development of islets depend on the interactions between cells and the surrounding 
ECM. During rat pancreatic development, the alpha subunits that commonly associate 
with β1 integrin: α3, α5, and α6, all have higher mRNA levels at e18 and p28 compared 
to day of birth (p0) where there is a marked decrease (Yashpal et al. 2005). β1 integrin 
along with α3 and α6 protein also significantly increase over the period from p0 to p28 
implicating its important role during the maturation and proliferative phase of rat 
pancreas development (Yashpal et al. 2005). Human fetal islets demonstrate a similar 
trend, with an increase in α3β1 and α6β1 observed by 16-20 weeks of development 
(Wang et al. 2005). Previous studies demonstrated that human fetal pancreatic cells 
migrate and interact with collagen IV matrix protein exclusively through interactions 
with α1β1 integrin (Kaido et al. 2004a). Similarly, αvβ1 in 19-21 week old human fetal 
islets has been shown to be essential for spreading and migration on vitronectin, an ECM 
component expressed by epithelial cells and insulin-expressing cells emerging from the 
ductal epithelium (Cirulli et al. 2000, Kaido et al. 2004b). In studies examining 
developing human and rat islets, a significant reduction of islet cell adhesion to the ECM 
was observed when cells were treated with a functional blocking β1 integrin antibody 
(Yashpal et al. 2005, Wang et al. 2005). Recently, Diaferia and colleagues (2013) 
generated a beta-cell specific β1 integrin knockout model using Cre recombinase 
downstream of the rat insulin-1 promoter (RIPβ1KO mice). This model, in which β1 
integrin was knocked out from conception, resulted in a significant reduction in beta-cell 
mass (18% of that seen in controls) (Diaferia et al. 2013). These results show that the 
interaction between beta-cells and the ECM surrounding them, as mediated by β1 
integrin, is essential for proper beta-cell proliferation during development and into 
adulthood. 
1.7 β1 integrin in islet survival and function 
A lot of work has been done to elucidate the role of β1 integrin in islet cell survival and 
function.  Early studies examining isolated canine islets found that they underwent 
apoptosis due to destruction of the perinsular-basement membrane, but had improved 
survival when cultured in the presence of collagen I and fibronectin, which are two ECM 
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ligands of β1 integrin (Wang & Rosenberg, 1999).  Most work regarding β1 in pancreatic 
islets has been conducted in vitro. One of the first studies found that α3β1 represents 
nearly half of the β1 integrins on primary and transformed (RIN-2A line) rat islet cells, 
and when this interaction is blocked, the islets have reduced attachment and spreading on 
bovine corneal ECM or ECM produced by A-431 cells (Kantengwa et al. 1997). 
Similarly, Parnaud (2006) found that blocking the interaction between β1 integrin and 
laminin-5, led to reduced insulin secretion and beta-cell spreading, whereas culturing rat 
islets on an 804G matrix that is rich in laminin-5 enhanced insulin secretion. 
Furthermore, the 804G matrix protects beta-cells from apoptosis via activation of the 
FAK/MAPK/ERK1/2 pathway (Hammer et al. 2004). Although the primary ligand of 
α3β1 is laminin, it has been shown that it can bind to a series of other matrix proteins 
including collagen, fibronectin, and laminin, and this is typically found in situations 
where another primary integrin is absent (Kantengwa et al. 1997). Studies using the 
insulinoma-1 cell line (INS-1), a beta-cell cancer line that secretes insulin in response to 
glucose within physiological ranges (Asfari et al. 1992), observed that β1 integrin 
associates with α1-α6 and αV in these cells, and α3β1 was the most highly expressed 
(Krishnamurthy et al. 2008). INS-1 cells also showed beneficial effects when cultured on 
collagen I and IV, whereby increased levels of spreading, survival, proliferation, and 
FAK activation are observed, and these beneficial effects are negated when α3β1 is 
blocked (Krishnamurthy et al. 2008). Studies using human fetal islets have found similar 
results, where interfering with β1 integrin either through blockade or siRNA leads to 
reduced Insulin gene expression, increased apoptosis, reduced ECM adhesion, and 
reduced p-FAK and p-ERK1/2 levels (Wang et al. 2005, Kaido et al. 2004b, Saleem et al. 
2009). Examination of rat and human fetal islets also showed that either transfections 
with siRNA against β1 or utilization of a β1 immunoneutralizing antibody leads to an 
increase in apoptosis and a reduction in Pdx-1 and Insulin mRNA (Wang et al. 2005, 
Yashpal et al. 2005). Important to note is that Pdx-1 is not only responsible for proper 
development of the pancreas, it also plays a key role in insulin gene expression in mature 
beta-cells (Fujimoto and Polonsky, 2009). All of these in vitro studies highlight a role for 
β1 integrin in maintaining islet function and survival, however the in vivo role of β1 
integrin has only recently begun to be elucidated. 
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In more recent years with the advancement of in vivo gene knockdown techniques, mouse 
models have been generated to study the relationship between integrins, the ECM and 
beta-cells. One study analyzed the role of β1 integrin by conditionally removing it in 
collagen Ia2-producing cells of adult mice using a CreERT-loxP system (β1KO mice) 
(Riopel et al. 2011). This knockout impacted beta-cells, but also affected a variety of 
other cell types; this includes pancreatic stellate cells (PaSC), which are fibroblast-like 
cells that are a major contributor of ECM proteins in the pancreas (Apte et al. 2012). In 
this model the pancreas became very dissociated, with some islets having no contact with 
exocrine cells, presumably due to the reduction in collagen fibers and connective tissue 
that was observed. In addition, β1KO mice developed glucose intolerance while still 
responding normally to exogenous insulin, indicating that hyperglycemia in mice was due 
to beta-cell defects (Riopel et al. 2011). The β1KO mice had reduced beta-cell mass due 
to a decrease in proliferation and an increase in apoptosis, a decrease in islet insulin 
content and reduced Pdx-1 protein levels.  A decrease in FAK/ERK1/2 were also seen in 
β1KO mice, which corroborates previous in vitro studies that imply that β1 regulates 
survival and function of islets through this pathway (Hammer et al. 2004, Krishnamurthy 
et al. 2008, Saleem 2009). Since the ablation of β1 integrin was not specific to beta-cells, 
it is unclear whether the loss of β1 integrin played a direct or indirect role in islet cell 
function and survival.  
As previously mentioned, the RIPβ1KO model has been generated for use as a beta-cell 
specific β1 knockout mouse model (Diaferia et al. 2013). However, the knockout is 
present in beta-cells as soon as the Insulin gene is transcribed at the beginning of 
embryonic development. Despite the significantly reduced beta-cell mass in adult 
RIPβ1KO mice (~18% of that seen in wild-type), islet architecture was unchanged and 
insulin content was significantly increased in the remaining beta-cell population (Diaferia 
et al. 2013).  These islets lacking β1 integrin also secreted significantly more insulin in 
response to glucose during an IPGTT and resulted in maintenance of normoglycemia. 
One possible explanation proposed is that β3 and β5 integrins have crosstalk capabilities 
that can compensate for β1 integrin when it is blocked or genetically ablated (Diaferia et 
al. 2013). The ability for these integrin subunits to compensate, and the fact that the 
knockout was induced at conception, leaves ample time during development for this 
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compensatory response. Although other integrins may have been able to maintain the 
functional role of beta-cells, this study shows that β1 is a key regulator of cellular 
proliferation in beta-cells. Positive regulators of cell-cycle arrest were up-regulated in 
RIPβ1KO mice, such as cyclin dependent kinase 1A, cyclin dependent kinase 5 
regulatory subunit associated protein 1, and ERK-dependent tumour suppressors (e.g., 
deleted in malignant brain tumors 1). Paralleling these findings was a reduction in cyclin 
D1, a protein required for progression through the G1 phase of the cell cycle that has 
been established to be essential in postnatal beta-cell growth (Kushner et al. 2005). The 
formation of focal-adhesions is the way by which integrins regulate outside-in signalling, 
and the RIPβ1KO model showed a significant decrease in p-ERK1/2 and p-Akt within 
these islets. The mechanism by which these proteins regulate beta-cells and the specific 
proteins involved are discussed now.  
1.8 Signalling pathways involving β1 integrin in islet survival 
and function 
When integrins are activated they interact with the band 4.1, ezrin, radixin and moesin 
homology (FERM) domain on FAK (Lim et al. 2008), which leads to 
autophosphorylation of tyrosine residue 397 either through direct interaction with 
integrins or through the phosphorylation of FAK tyrosine residues 576 and 577 by proto-
oncogene tyrosine kinase Src (Schaller 2001). Src can be activated by a variety of 
tyrosine phosphatases (Brakebusch & Fassler, 2003) and it interacts with the focal 
adhesion complex through its SH2 domain which binds to FAK autophosphorylation 
domains, or through is SH3 domain which interacts with paxillin (Clark & Brugge, 
1995). The binding of Src leads to recruitment of SH2-SH3 adaptor proteins through 
further modifications of FAK (Clark & Brugge, 1995), one of which being the 
phosphorylation of FAK at tyrosine 925 (p-FAKY925), leading to the subsequent binding 
of growth factor receptor-bound protein 2 (Grb2) and the Ras guanine nucleotide 
exchange factor mSOS1 (son of sevenless homolog 1) (Giancotti & Ruoslahti, 1999). 
This leads to downstream phosphorylation of kinases Ras and rapidly accelerated 
fibrosarcoma (Raf), which causes activation of the MAPK/ERK1/2 pathway. ERK1/2 can 
regulate cell proliferation and survival in a variety of ways once activated. ERK1/2 has 
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been shown to induce NCK5a neuronal CDK5 activator (p35) expression, a known 
activator of cyclin-dependent kinase 5 (CDK5) (Harada et al. 2001). Together, CDK5 and 
ERK1/2 can promote cell cycle progression and prevent apopotosis through 
phosphorylating the anti-apoptotic protein b-cell lymphoma 2 (Bcl2) on residues 
threonine 56, 74 or serine 84 which promotes the release of apoptotic proteins from the 
mitochondria (Wang et al. 2006, Stupack & Cheresh, 2002). Additionally, ERK1/2 can 
prevent caspase-mediated apoptosis by inhibiting caspase 9 activity (Allan et al. 2003). 
One group of researchers generated a rat insulin 1 promoter-driven FAK knockout 
(RIPFAKKO) and found that when beta-cell FAK is diminished, CDK5, ERK1/2 and 
Bcl2 activity are significantly reduced along with decreased beta-cell mass (Cai et al. 
2012). This finding brings together the multitude of studies that have previously shown 
links between reduced beta-cell survival and decreased FAK/ERK1/2 pathway signalling 
due to an impairment of normal β1 function or levels (Hammer et al. 2004, 
Krishnamurthy et al. 2008, Saleem 2009, Riopel et al. 2011, Diaferia et al. 2013).  
As mentioned before, the activation of Src by FAK can lead to the recruitment of SH2-
SH3 adaptor proteins, one of which is the p85 subunit of PI3K, which allows for the 
catalytic activity of phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
alpha (p110) (Xia et al. 2004). Downstream of PI3K/p110 activation, Akt becomes 
phosphorylated at serine 473 (p-AktS473) (McLean et al. 2005, Xia et al. 2004). The 
activation of AktS473 has been shown to prevent apoptosis in a variety of different 
manners, like that of ERK1/2 through the regulation of capase-9 and BAD which directly 
interacts with Bcl2, preventing its anti-apoptotic properties (Song et al. 2005). In 
addition, reduced p-AktS473 signaling was found in RIPβ1KO mice, which suggests a role 
in the reduction in beta-cell mass and increased cell death (Cai et al. 2012). The 
RIPFAKKO model also showed a significant reduction in p-AktS473 which could be 
playing a similar role in this model regarding cell survival (Cai et al. 2012). 
The role of FAK mediated signalling has also been shown to play a role in glucose 
stimulated insulin secretion through cytoskeletal remodelling (Kalwat & Thurmond 2013, 
Ronadas et al. 2011, Rondas et al. 2012, Cai et al. 2012). Once activated by FAK 
phosphorylation, paxillin directly interacts with the cytoskeleton through interactions 
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with vinculin and actopaxin, and these interactions are partly responsible for actin 
remodeling through depolymerization (reviewed in Turner 2000). A recent study used 
MIN6B1 cells (Rondas et al. 2012) to knock down β1 integrin or FAK and found that 
glucose-induced disruption of F-actin, which is required for proper granule movement to 
the plasma membrane, was hindered. Additionally, phosphorylated paxillin at tyrosine 
118 (p-paxillinY118), along with p- ERK1/2 were decreased during glucose stimulation 
along with the glucose-induced activation of the Akt/AS160 signalling pathway (Rondas 
et al. 2012). Using rat beta-cells or isolated islets (Rondas et al. 2011) and hindering FAK 
or paxillin function, similar results were noted along with a reduction in SNARE proteins 
such as SNAP25 and syntaxin 1. Using the RIPFAKKO mouse model, a reduction in 
FAK also lead to reduced p-paxillinY118 and colocalization of it with SNAP25 and 
syntaxin 1 on the plasma membrane was reduced (Cai et al. 2012). These findings 
highlight the essential role of FAK mediated signalling not only in beta-cell survival but 
also in mediating insulin exocytosis through cytoskeletal remodeling (Figure 1.3) 
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Figure 1.3 β1 integrin signalling pathway 
Outside-in signalling as mediated by β1 integrin is due to the formation of focal adhesion 
complexes. When focal adhesion kinase (FAK) becomes phosphorylated it leads to the 
activation of downstream signalling molecules through a kinase cascade resulting in 
regulation of cell proliferation, survival, differentiation and glucose metabolism. 
Additionally, the focal adhesion complex is responsible for cytoskeletal remodelling 
essential for insulin exocytosis. 
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1.9 Rationale and objectives of the present study 
The rationale of this project is to elucidate the role of β1 integrin in beta-cells of adult 
mice without the confounding variables of development (Diaferia et al. 2013) or non-beta 
cell specificity (Riopel et al. 2011) seen in previous mouse models. A new inducible 
β1KO model where CreERT is downstream of the mouse insulin-1 promoter (MIP) was 
generated (MIPβ1KO) to remove these variables and determine the precise role of β1 
integrin in beta-cells of adult mice. 
Objective 
To utilize the MIPβ1KO mouse model to elucidate the role of β1 integrin specifically in 
the beta-cells of adult mice.  
 
Hypothesis  
Beta-cell specific β1 integrin knockout in adult mice will lead to glucose intolerance, 
impaired beta-cell function, and survival. 
 
Specific Questions 
1. Do adult MIPβ1KO mice display impaired glucose tolerance and insulin secretion? 
2. Are insulin secretory molecules altered in MIPβ1KO mice? 
3. Does a beta-cell specific knockout of β1 integrin in adult mice lead to reduced beta-
cell mass and increased beta-cell death? 
4. Are there alterations in transcription factor expression in MIPβ1KO mice? 
5. Does a beta-cell specific knockout of β1 integrin in adult mice affect islet 
vascularization? 
6. Are associated intracellular signaling pathways affected in MIPβ1KO islets? 
7. Does  integrin expression change in MIPβ1KO mice? 
8. Do aged MIPβ1KO mice recover from the initial knockout of β1 integrin? 
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2 Chapter 2 – Materials and Methods 
2.1 Generation of the beta-cell β1 integrin knockout mouse 
model 
The mouse insulin 1 promoter-driven Cre recombinase mouse line (MIP-CreER) was a 
gift from Dr. Louis Philipson’s laboratory (University of Chicago, Chicago, IL, USA) 
(Tamarina et al. 2014). To verify the specificity of the CreER transgene, MIP-CreER 
mice were crossed with B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J mice (Jackson 
Laboratory, Stock # 007905). Cre expression in the MIP-CreER mice excised the LoxP-
stop-LoxP signal 5’ to the tdTomato gene and activated expression of the red 
fluorescence reporter protein exclusively in beta-cells of isolated islets (Trinder et al. 
2016). To generate the beta-cell specific β1 integrin knockout (MIPβ1KO) mouse line, 
C57Bl/6 mice with a LoxP floxed β1 integrin gene (B6;129-Itgb1tm1Efu/J), obtained from 
Jackson Laboratory (Stock #004605) were crossed with MIP-CreER mice within our 
vivarium (Victoria Research Laboratories, Victoria Hospital, London, ON, CA), 
producing MIP-CreER+/-;β1itgfl/+ mice. The MIP-CreER+/-; β1itgfl/+ mice were 
subsequently mated to generate the tamoxifen inducible β1 integrin knockout 
experimental mouse model MIPβ1KO (MIP-CreER+;β1itgfl/f) and control mice (MIP-
CreER-;β1itgfl/fl  and MIP-CreER+;β1itg+/+) (Figure 2. 1). All protocols were approved by 
the Animal Use Subcommittee at the University of Western Ontario in accordance with 
the guidelines of the Canadian Council of Animal Care (Appendix A). 
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Figure 2.1 Breeding schematic for generation of MIPβ1KO mice 
Heterozygote mice obtained from the initial crossing of MIP-CreERT 
mice with B6;129-Itgb1tm1Efu/J mice lead to six different potential 
phenotypic combinations. The experimental mice that were used were the 
control mice (MIP-CreERT+;Itgb1+/+ and MIP-CreERT-;Itgb1fl/fl, blue) 
and MIPβ1KO mice (MIP-CreERT+;Itgb1fl/fl, red). Percentages of the 
likelihood of any given genotype are listed.  
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2.2 Mouse genotyping  
For genotyping, approximately 1-3mm of tail from each mouse was collected at weaning, 
then dissolved and heated in 50 μL base solution (25 mM NaOH; 0.2 mM EDTA) at 
95°C for 30 minutes, and allowed to cool to room temperature for 1 hour. Subsequently, 
50 μL of Tris-HCl (pH 5.5) was then added to neutralize each sample and were 
centrifuged at 15000 x g for 1 minute. Polymerase chain reactions (PCR) were used to 
confirm the genotype using the following primers: MIP (5’-CCT GGC GAT CCC TGA 
ACA TGT CCT-3’) and CreERT (5’-TGG ACT ATA AAG CTG GTG GGC AT-3’), 
whereas β1itgfl/fl was detected using oIMR1906 (5’-CGG CTC AAA GCA GAG TGT 
CAG TC-3’) and oIMR1907 (5’-CCA CAA CTT TCC CAG TTA GCT CTC-3’). A 2% 
agarose gel with ethidium bromide was used to verify the PCR amplicons. The gels were 
run at 80 V for 90 minutes and imaged using the Gene Genius Bio Imaging System 
(SynGene, Frederick, MD, USA) along with GeneSnap 7.12 software (SynGene). 
MIPCreERT+   mice were identified by the corresponding MIPCreERT DNA fragment at 
268 base pairs (BP) (Figure 2.2A), while β1itg+/+ and β1itgfl/fl mice produced a single 
DNA fragment size of either 160bp or 280bp, respectively (Figure 2.2B).  
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 MIPCreERT+ (268bp)  
 Itgβ1+/+(160bp) & Itgβ1fl/fl (280bp)  
Figure 2.2 Representative PCR images for mouse genotyping 
A) MIPCreERT+  positive mice are indicated by one distinct band located at 
268bp. B) Itgβ1 mice are either heterozygous for the wildtype and mutant 
alleles and display two bands at 160bp and 280bp (Itgβ1+/fl, yellow arrow), 
homozygous for the wildtype alleles at 160bp (Itgβ1+/+, blue arrow) or 
homozygous for the mutant alleles at 280bp (Itgβ1fl/fl, red arrow). 
 
A 
B 
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2.3 Tamoxifen preparation and administration 
Tamoxifen (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 100% ethanol to a 
final concentration of 300 mg/mL. The sample was heated at 60°C and vortexed until the 
tamoxifen was completely dissolved. For injections, the ethanol-suspended tamoxifen 
was diluted in corn oil (Sigma-Aldrich, St. Louis, MO, USA) to a final concentration of 
30 mg/mL. Mice were injected intraperitoneally (I.P.) at 3-4 weeks of age for three 
consecutive days at a dosage of 4 mg per 20 g of body weight (BW). 
2.4 Glucose metabolism studies 
An intraperitoneal glucose tolerance test (IPGTT) was conducted at 4, 8, 16 (females 
only), or 25-35 weeks post-tamoxifen injection in MIPβ1KO and control mice to measure 
the response of mice to high glucose levels. For the IPGTT, glucose (D-(+)-glucose; 
dextrose; Sigma-Aldrich, St. Louis, MO, USA) was administered intraperitoneally at a 
dose of 2 mg/g of BW after a 16 hour overnight fast, and blood glucose levels were 
measured at 0, 15, 30, 60, 90, and 120 minutes post injection (as reported in Riopel et al. 
2011). Area under the curve (AUC) was used to quantify glucose responsiveness using 
units of ([mmol/L x minute)] (Allison et al. 1995, Krishnamurthy et al. 2007). 
Glucose-stimulated insulin secretion (GSIS) was performed at 8 weeks (males) or 16 
weeks (females) post-tamoxifen, following an overnight fast of 16 hours. Plasma blood 
samples via tail vein were collected at 0 minutes before an IP glucose injection (2 mg/g 
BW), and at 5 and 35 minutes after glucose loading (Riopel et al. 2011). The blood 
samples were centrifuged for 20 minutes at 15871 x g at 4°C and plasma was stored at     
-20°C.  
An intraperitoneal insulin tolerance test (IPITT) was conducted at 8 weeks (male) and 16 
weeks (female) in MIPβ1KO and control mice to insulin sensitivity. Following a 4 hour 
fast (starting at 9AM), 1 U/kg BW of human insulin (Humalin, Eli Lilly, Toronto, 
Ontario, Canada) was administered via IP injection, and blood glucose levels were 
measured at 0, 15, 30, 60, 90, and 120 minutes post injection (Riopel et al. 2011). Data 
24 
 
was expressed as the percent change from basal blood glucose levels and AUC was used 
for quantification [(mmol/L x minute)] (Allison et al. 1995, Krisnamurthy et al. 2007, 
Feng et al. 2013). 
2.5 Islet isolation 
Islets from both MIPβ1KO and control mice at 8 weeks and 16-week post-tamoxifen 
injection were isolated using the following methodology: the common bile duct was 
sutured closed via surgical string in close proximity to the duodenum and 3 mL of 
collagenase V (1 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) was injected via bile duct 
to perfuse the pancreas. The pancreas was then dissociated in a 15 mL falcon tube with 3 
mL dissociation buffer (Hank’s balanced salt solution with HEPES) and incubated in a 
37°C hot water bath for 30 minutes.  Islet purification was performed using a Ficoll 
gradient as previously described (Wang et al. 2004), and processed for RNA or protein 
extraction as well as for ex vivo GSIS. 
2.6 Ex vivo GSIS 
For ex vivo GSIS, duplicate samples with 10 islets per experimental group were hand-
picked and incubated in RPMI 1640 (11% glucose) overnight for recovery culture. The 
overnight culture media was collected for basal insulin secretion levels. Islets were 
washed in glucose-free media and incubated in the following manner: a low glucose 
media (2.2 mM) for 1 hour, then in a high glucose solution (22 mM) for 1 hour, and a 
final 1 hour incubation in an additional low glucose media (2.2 mM) (Feng et al. 2012). 
The media from each incubation stage was collected and stored at -20°C, and islets were 
washed and stored in PBS at -20°C. Insulin secretion and content were measured using 
the Mouse Ultrasensitive Insulin Enzyme Linked Immunosorbent Assay (ELISA) kit 
(ALPCO, Salem, NH, USA).  
2.7 Insulin ELISA 
Islet insulin secretion and content was measured using a mouse ultrasensitive insulin 
ELISA kit (ALPCO, Salem, NH, USA) with a sensitivity of 0.15 ng/mL, according to the 
manufacturer’s instructions. Insulin release was expressed as ng/mL. A static glucose 
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stimulation index in isolated islets was calculated by dividing the insulin output from the 
high glucose (22 mM) incubation by the insulin output during the low glucose (2.2 mM) 
incubation. 
2.8 Tissue processing and immunohistological analyses 
Mice were sacrificed at 8 weeks (male) or 16 weeks (female) post-tamoxifen, or at 25-35 
weeks post-tamoxifen for aged cohorts, and their pancreata were fixed in 4% 
paraformaldehyde overnight at 4°C (Fisher Scientific Company, Ottawa, ON, Canada). 
Tissue was washed in phosphate buffered saline (PBS) and subjected to a series of 
dehydration steps (70%-100% ethanol), toluene, and paraffin wax (Fisher Scientific 
Company, Ottawa, ON, Canada) using the Shandon CitadelTM Tissue Processor 1000 
(Thermo Electron Corporation, Waltham, MA, USA). Embedded tissue was cut into 3 
μm thick sections using the Leica RM2245 microtome (Leica Biosystems, Concord, ON, 
Canada) and placed on a heat plate at 37°C overnight.  
For immunofluorescence staining, slides were deparaffinized and rehydrated starting with 
three separate xylene washes and a series of ethanol (100% to 70%) solutions, and finally 
washed in PBS. To recover epitopes masked during paraformaldehyde fixation, slides were 
placed in a sodium citrate antigen retrieval solution (pH 6.0) (Bouwens et al. 1997) and 
heated in a microwave for 20 minutes. A 10% normal goat serum solution (Invitrogen, 
Frederick, MD, USA) was applied for 30 minutes at room temperature to prevent non-
specific antibody binding. Primary antibodies were applied using the manufacturers’ 
recommended dilutions listed in Table 2.1, and incubated overnight at 4°C. Secondary 
antibodies were used at a 1:50 dilution as follows: fluorescein isothiocyanate (FITC anti-
mouse, anti-rat, or anti-rabbit) or TexRed (anti-mouse, anti-rat, or anti-rabbit) (Jackson 
ImmunoResearch, West Grove, PA, USA). Nuclei were stained with DAPI (4’-6-
diamidino-2-phenylindole) (Sigma-Aldrich, St. Louis, MO, USA) at a dilution of 1:1000 
(coverslips were subsequently secured and the slides were stored at -20°C away from light 
exposure. Images were obtained using the Leica DMIRE2 fluorescence microscope 
(Improvision, Lexington, MA, USA) and quantified using Image-Pro software 
(MediaCybernetics, Rockville, MD, USA).   
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Immunohistochemical staining was conducted for detection of the transcription factor 
MafA. The rehydration and blocking steps were the same as previously mentioned. For 
secondary antibody application, astreptavidin-biotin horseradish peroxidase complex and 
aminoethyl carbazole substrate kit was used (Invitrogen, Frederick, MD, USA) after 
incubation with the primary antibody. The slides were counter-stained using Hematoxylin 
(Thermo Scientific, Burlington, ON, Canada). Images were obtained with the Leica upright 
light microscope (Improvision, Lexington, MA, USA) and quantified using Image-Pro 
software (MediaCybernetics Rockville, MD, USA).  
An islet was defined as any cluster of 3 or more insulin+ cells with at least one non-beta 
cell. Islet density (islet number per mm2) was obtained by measuring all islets on the 
pancreatic sections and dividing that number by the total pancreas area. Islet size was 
calculated by measuring all islets’ area (μm2) per tissue section and then sorted into 
subgroups based on size, with data being expressed as a percentage of total islet number. 
Alpha and beta-cell mass was determined by manually tracing the glucagon+ or insulin+ 
area and pancreatic section area, and the data was calculated as follows: alpha-cell mass 
(mg) = (glucagon+ area x pancreas mass)/pancreas area; beta-cell mass (mg) = (insulin+ 
area x pancreas mass)/pancreas area, as previously described (Wang et al. 1994).  
Quantification of beta-cell nuclear proteins was conducted using double 
immunofluorescence staining for Ki67, Pdx-1, Nkx6.1, Nkx2.2 or Isl-1 with insulin. A 
total of 10 random islets were selected per sample and analyzed using Image-Pro software 
(MediaCybernetics). Insulin+ cells that co-stained with a nuclear transcription factor (TF) 
were quantified and expressed as a percentage of double positive labelling cells divided by 
the total number of insulin+ cells. 
Platelet endothelial cell adhesion molecule (PECAM) was used as a co-stain with insulin 
to identify vasculature in islets.  For analyses, 10 random islets were selected and their 
capillaries and total islet size was manually traced. Islet capillary area was measured by 
taking the combined area of all capillaries within an islet and dividing it by the total islet 
area, and was expressed as a percentage. The average islet capillary diameter was measured 
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as the total diameter of all islet capillaries divided by the total number of capillaries and 
expressed as a mean (m2) (Feng et al. 2015). 
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Table 2.1 Primary antibodies used for immunostaining and Western Blots 
Primary Antibodies  Dilution Company 
Anti-Akt Rabbit polyclonal 1:3000* Cell Signaling (Temecula, CA, USA) 
Anti-Cyclin D1 Mouse monoclonal 1:2000* Cell Signaling (Temecula, CA, USA) 
Anti-E-Cadherin Rabbit polyclonal 1:200 Cell Signaling (Temecula, CA, USA) 
Anti-ERK Rabbit polyclonal 1:3000* Cell Signaling (Temecula, CA, USA) 
Anti-FAK Rabbit polyclonal 1:1000* Cell Signaling (Temecula, CA, USA) 
Anti-Glucagon Rabbit polyclonal 1:800 Sigma-Aldrich (St Louis, MO, USA) 
Anti-Glut2 Rabbit polyclonal 1:200 Abcam (Cambridge, MA, USA) 
Anti-Insulin Mouse monoclonal 1:800 Sigma-Aldrich (St Louis, MO, USA) 
Anti-Insulin Rabbit polyclonal 1:50 Santa Cruz (Santa Cruz, CA, USA) 
Anti-Integrin α3 Rabbit polyclonal 1:50 Chemicon (Temecula, CA, USA) 
Anti-Integrin α5 Rabbit polyclonal 1:50 Chemicon (Temecula, CA, USA) 
Anti-Integrin α6 Rabbit polyclonal 1:50 Santa Cruz (Santa Cruz, CA, USA) 
Anti-Integrin αV Rabbit polyclonal 1:100 Abcam (Cambridge, MA, USA) 
Anti-Integrin β1 Rabbit polyclonal 1:500* Abcam (Cambridge, MA, USA) 
Anti-Integrin β1 Rat monoclonal 1:100 Milipore (Etobicoke, ON, CA) 
Anti-Islet1 Mouse monoclonal 1:100 DSHB (Iowa City, IA, USA) 
Anti-Ki67 Rabbit polyclonal 1:100 Abcam (Cambridge, MA, USA) 
Anti-MafA Rabbit polyclonal 1:100 Bethyl Laboratory (Montgomery, TX, 
USA) 
Anti-Munc18-1 Rabbit polyclonal 1:100 Abcam (Cambridge, MA, USA) 
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Anti-Nkx2.2 Mouse monoclonal 1:100 DSHB (Iowa City, IA, USA) 
Anti-Nkx6.1 Mouse monoclonal 1:100 DSHB (Iowa City, IA, USA) 
Anti-PARP Rabbit polyclonal 1:1000* Cell Signaling (Temecula, CA, USA) 
Anti-Pdx-1 Rabbit polyclonal 1:800 
1:2000* 
Dr. Wright (University of Vanderbilt, 
Nashville, TN, USA) 
Anti-PECAM Rabbit polyclonal 1:200 Santa Cruz (Santa Cruz, CA, USA) 
Anti-phospho-Akt 
(Ser473) 
Mouse monoclonal 1:2000* Cell Signaling (Temecula, CA, USA) 
Anti-phospho-
Cleaved PARP 
Rabbit polyclonal 1:1000* Abcam (Cambridge, MA, USA) 
 
Anti-phospho-ERK 
(Thr202/Tyr204) 
Rabbit polyclonal 1:3000* Cell Signaling (Temecula, CA, USA) 
Anti-phospho-FAK 
(Tyr397) 
Rabbit polyclonal 1:2000* Cell Signaling (Temecula, CA, USA) 
Anti-SNAP25 Mouse monoclonal 1:50 Santa Cruz (Santa Cruz, CA, USA) 
Anti-Syntaxin 1A Mouse monoclonal 1:50 Santa Cruz (Santa Cruz, CA, USA) 
Anti-VAMP2 Rabbit polyclonal 1:200 Abcam (Cambridge, MA, USA) 
Anti-β-actin Mouse monoclonal 1:5000* Sigma-Aldrich (St Louis, MO, USA) 
* Indicates dilution factor used when conducting a western blot. DSHB stands for 
Developmental Studies Hybridoma Bank at the University of Iowa. 
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2.9 RNA extraction 
RNA was extracted from isolated mouse islets via the RNAqueous-4 PCR Kit as per the 
manufacturer’s instructions (Ambion, Austin, TX, USA). Cell lysate was then vortexed 
intermittently and washed with 64% ethanol (Life Technologies, Carlsbad, CA, USA). A 
collection filter was used to isolate RNA (Life Technologies, Carlsbad, CA, USA), and 
heated elution solution (Life Technologies, Carlsbad, CA, USA) was applied to collect the 
RNA from the filter. DNA contamination was eliminated by DNase treatment (Life 
Technology, Carlsbad, CA, USA). The concentration of RNA was measured using a 
Multiskan Spectrometer (Thermo Scientific, Burlington, ON, Canada), and only samples 
with a concentration greater than 0.1 μg/μL were used. RNA quality was confirmed by 
observation of a 28S and 18S band when run on a 1% agaroses ethidium bromide infused 
gel.  
2.10 qRT-PCR quantification 
Quantitative real-time reverse transcriptase PCR (qRT-PCR) was conducted with 0.1 μg of 
cDNA using the iQ SYBR Green Supermix kit (Bio-Rad Laboratories, Mississauga, ON, 
Canada), along with 0.5 μL forward and reverse primers (Table 2.2). To verify primer 
specific amplification, the reactions were performed by omitting reverse transcriptase (RT-
), cDNA, or DNA polymerase and no reaction bands were observed. Reactions were run 
using the Bio-Rad CFX Connect™ real-time PCR detection system (Bio-Rad Laboratories, 
Mississauga, ON, Canada) and analyzed using CFX Manager software (Bio-Rad 
Laboratories). Relative mRNA levels were calculated using the 2-ΔΔCT method, where ΔCT 
is the difference between the threshold cycle of a given cDNA transcript and the internal 
standard gene 18S rRNA subunit cDNA (Schmittgen et al. 2008). The derivative melting 
curves were analyzed to assess amplification specificity of the target gene sequence 
(Figure. 2.3). 
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Table 2.2 Sequences of primers used in qRT-PCR 
Primer 
Accession 
Definition 
Sequence 5’-3’ 
(Sense/Antisense) 
Fragment 
Size (bp) 
Annealing  
Temp (°C) 
Glucagon NM_008100.4 
 
GAT CAT TCC CAG CTT CCC AG 
CGG TTC CTC TTG GTG TTC AT 
163 56.5 
Ins1&2 
 
NM_008386.3 
NM_008387.4 
 
GGC TTC TTC TAC ACA CCC A 
CAG TAG TTC TCC AGC TGG TA 
182 53.9 
Itga3 (α3) NM_013565.2 
 
GCC ATC CGC CCT GCT ACT GT 
AGT ACG GGC TGC AAG TTG TCC 
219 60.9 
Itga5 (α5) NM_010577.3 
 
GGC ACC CAA GGC TAA CAC TA 
CGA ACT GTT GCT CCG AAC CA 
204 57.7 
Itga6 (α6) NM_008397.3 
 
TGG CTT CCT CGT TTG GCT ATG 
GAA TCG GCT TCA CAT TAC TC 
168 54.2 
ItgaV (αV) NM_008402.2 
 
ACC TGG ACG TCG AAA GTC CC 
CCG GCG GCT GGA TGA GCA TT 
194 59.4 
Itgb1 (β1) NM_010578.2 
 
GGC AAC AAT GAA GCT ATC GTG 
TTC GGA TTG ACC ACA GTT GTC 
257 55.1 
Pdx1 NM_008814.3 
 
CCA CCC CAG TTT ACA AGC TCG 
GTA GGC AGT ACG GGT CCT CT 
324 57.5 
Snap25 NM_011428.3 
 
GGC TTC ATC CGC AGG GTA AC 
CTG GCG ATT CTG GGT GTC AAT 
138 58.9 
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Syntaxin1A NM_016801.3 AAG GAC AGC GAT GAC GAC GAC 
TTC GGC AAT CTT GTC AAT AA 
114 55.5 
Syntaxin3 NM_001025307.1 
 
GTC GGC ACA AGG ACA TCG TA 
TGT TCT CAA TGC GGT CAA TCA 
117 56.5 
Vamp2 NM_009497.3 
 
GAG CGG GAC CAG AAG TTG TC 
TCC ACC AGT ATT TGC GCT TG 
109 57.8 
18S NR_003278.3 
 
GTA ACC CGT TGA ACC CCA TTC 
CCA TCC AAT CGG TAG TAG CG 
151 55.6 
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Glucagon 
Insulin 
Figure 2.3. The derivative melting curves of qRT-PCR products. 
The derivative melting curves (arrows) of glucagon and insulin show that qRT-PCR 
assays have amplified specific target sequences.  
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2.11 Reverse transcription and cDNA synthesis 
Oligo-(dT) (500 μg/ml), DEPC, and random hexamers (3000 ng/mL) were added to the 
RNA and heated for 5 minutes at 60°C and then cooled down to 4°C for 5 minutes using 
the GeneAmp PCR System 2400 (Applied Biosystems INC., Foster City, CA, USA). 
Afterwards, 4 μL of 5x buffer, 2 μL of DTT, 2 μL of 10 mM dNTPs and 0.5 μL of RNAsin 
was mixed together and added to the RNA sample. The GeneAmp PCR System (Applied 
Biosystems) was used to heat samples in the following order: 42°C for 90 minutes, 94°C 
for 5 minutes, and 4°C for 60 minutes. SuperScript® II Reverse Transcriptase (200 units) 
(Invitrogen) was added with the samples at 42°C and a final concentration of 6 μg/ 8 μL 
was obtained by dilution with sterile H2O and stored at -20°C. Samples omitting 
SuperScript® II Reverse Transcriptase were used as negative controls. 
2.12 Protein extraction and western blot analyses 
Isolated islets were lysed in Nonident-P40 lysis buffer (Nonident-P40, 
phenylmethylsulfonyl fluoride, sodium orthovanadate) (Sigma-Aldrich, St. Louis, MO, 
USA) and a cOmplete™ protease-inhibitor cocktail tablet (Roche Applied Science, Quebec 
City, QC, Canada) using a sonicator, and then placed on ice for 30 minutes afterwards and 
spun down at 15871 x g for 20 minutes at 4°C before storage at -80°C (Riopel et al. 2011). 
A Bradford protein assay was conducted using the Bio-Rad dye reagent (Bio-Rad 
Laboratories, Mississauga, ON, Canada). Bovine serum albumin (BSA) standard 
concentrations at 0, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/mL were used for the standard 
curve. 10 μL of each standard and 1 μL of sample (added to 9 μL of sterile H2O) was 
pipetted onto a micro titer plate in duplicate. Once the dye was added to the samples, they 
were placed on a shaker for 20 minutes at room temperature. A Multiskan Spectrum 
spectrophotometer (Thermo Scientific, Burlington, ON, Canada) was used to read the 
optical density values at 595 nm.  
Protein was loaded at a concentration ranging from 15-20 μg into either a 7.5%, 10%, or 
12.5% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) resolving gel. 
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Electrophoresis was conducted at a rate of 40 V as it ran through the 4% stacking gel, and 
80 V for the remaining duration required to run to the bottom of the resolving gel. 
Nitrocellulose membranes (Bio-Rad Laboratories, Mississauga, ON, Canada) were used 
for protein transfer. The transfer was conducted at 250 mA for 150 minutes in an ice 
encased chamber containing transfer buffer (195 mM glycine, 25 mM Tris, and methanol 
at a volume of 20%). Membranes were treated with Ponceau S for approximately 1 minute, 
whereas gels were treated with Coomassie Blue for 30 minutes at room temperature to 
subjectively assess overall protein transfer. Membranes were then washed in Tris-buffered 
saline containing 0.1% Tween-20 (Zymed Laboratories, San Fran, CA, USA) to remove 
the Ponceau S. Blocking buffer was applied to the membranes for 30 minutes at room 
temperature (5% non-fat dairy milk, containing 2.5 mL 1x TBST and 50 μL NP-40 (Zymed 
Laboratories)). Primary antibodies (Table 2.1) were applied for 2 hours at room 
temperature, or overnight at 4°C, and the membranes were washed 3 times for 10 minutes 
in 1x TBST wash buffer prior to incubation with secondary antibodies. Anti-rabbit or anti-
mouse horseradish peroxidase-conjugated secondary antibodies were applied for 1 hour at 
room temperature (Cell Signaling Temecula, CA, USA). Proteins were detected using 
ECL™-Plus Western Blot detecting reagents (Perkin-Elmer, Wellesley, MA, USA) and 
imaged using the Versadoc Imaging System (Bio-Rad Laboratories). Image Lab (Bio-Rad 
Laboratories) was used to quantify the bands using densitometry and data were normalized 
to appropriate loading controls (e.g., β-Actin). 
2.13 Statistical analyses 
Data are expressed as means ± SEM. Statistical significance was determined using an 
unpaired student's t-test (GraphPad software; La Jolla, CA, USA). Differences were 
considered statistically significant when p < 0.05.  
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3 Chapter 3 - Results 
3.1 Characterization of β1 integrin expression in beta-cells 
of MIPβ1KO mice 
To confirm and quantify the knockdown of β1 integrin in MIPβ1KO mice, both mRNA 
and protein from isolated islets were analyzed. qRT-PCR analysis showed a significant 
reduction of β1 integrin mRNA (p < 0.01 vs. control, Figure 3.1A) and protein level (p < 
0.01, Figure 3.1B) of approximately 60% in the male MIPβ1KO islets compared to 
controls at 8 weeks post-tamoxifen. Immunofluorescence staining was used to 
qualitatively examine β1 integrin knockdown and showed a reduction of β1 integrin in 
the islets of MIPβ1KO mice compared to control mice (Figure 3.1C). However, the 
reduction of β1 integrin mRNA in isolated female MIPβ1KO islets at 16 weeks post-
tamoxifen showed no statistical significance due to high variability among the samples 
(Figure 3.2A). Both western blot and immunofluorescence staining showed slightly 
reduced levels of β1 integrin protein in the islets of female MIPβ1KO mice compared to 
controls (Figure 3.2B,C).  
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Figure 3.1 Confirmation of β1 integrin knockdown in 8 weeks post-tamoxifen male MIPβ1KO mice 
A) qRT-PCR for β1 integrin mRNA and B) western blot analysis for β1 integrin protein in control and 
MIPβ1KO islets, with a representative blot shown. C) Representative double immunofluorescence staining for 
β1 integrin (green) and insulin (red) in the islets of control and MIPβ1KO mice. Scale bar: 25 μm. Black bars: 
control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-5/group) **p < 0.01 vs. 
control group. 
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Figure 3.2 Confirmation of β1 integrin knockdown in 16 weeks post-tamoxifen female MIPβ1KO mice 
A) qRT-PCR for β1 integrin mRNA and B) western blot analysis for β1 integrin protein in control and 
MIPβ1KO islets, with a representative blot shown. C) Representative double immunofluorescence staining for 
β1 integrin (green) and insulin (red) in the islets of control and MIPβ1KO mice. Scale bar: 25 μm. Black bars: 
control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3/group). 
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3.2 MIPβ1KO mice display impaired glucose tolerance 
Fasting blood glucose levels were taken along with body weight measurements to assess 
phenotypic abnormalities. Male MIPβ1KO mice at 8 weeks post-tamoxifen showed no 
change in fasting blood glucose and BW compared to control mice (Figure 3.3A,B). 
However, fasting blood glucose level in female MIPβ1KO mice at 16 weeks post-
tamoxifen were significantly elevated (p < 0.05, Figure 3.4A) with no change in BW 
(Figure 3.4B). IPGTT and IPITT tests were performed to assess glucose metabolism. 
Male MIPβ1KO mice subjected to an IPGTT showed statistically significant elevations in 
blood glucose at 15, 30, and 90 minutes post glucose injection which corresponded with 
an significant increase in the overall AUC (p < 0.05, Figure 3.3C). Impaired glucose 
tolerance was also observed in female MIPβ1KO mice at 16 weeks post-tamoxifen with a 
significant elevation of blood glucose at 30 minutes, and a significant increase in the 
overall AUC (p < 0.05, Figure 3.4C). To examine if peripheral insulin sensitivity was 
altered in MIPβ1KO mice, an IPITT was conducted and both MIPβ1KO mice and control 
mice responded in a similar fashion at all time points with unchanged AUC in all testing 
groups (Figure 3.3D and Figure 3.4D). 
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Figure 3.3 Metabolic analyses of 8 weeks post-tamoxifen male MIPβ1KO mice 
A) Fasting blood glucose (16 hours) and B) body weight of male control and MIPβ1KO mice. C) 
IPGTT and D) IPITT analyses and their corresponding AUC data for control and MIPβ1KO mice. 
Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-
8/group). *p < 0.05 vs. control group. 
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Figure 3.4 Metabolic analyses of 16 weeks post-tamoxifen female MIPβ1KO mice 
A) Fasting blood glucose (16 hours) and B) body weight of female control and MIPβ1KO mice. C) 
IPGTT and D) IPITT analyses and their AUC for control and MIPβ1KO mice. Black bars: control, 
white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-8/group). *p < 0.05 vs. 
control group. 
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3.3 Deficient glucose-stimulated insulin secretion in male but 
not female MIPβ1KO mice 
Because the MIPβ1KO mice showed impairment in glucose tolerance, glucose-stimulated 
insulin secretion (GSIS) was measured both in vivo and ex vivo to determine beta-cell 
functional responsiveness. An in vivo GSIS test was performed in male MIPβ1KO mice 
at 8 weeks post-tamoxifen and showed significantly lower levels of plasma insulin at 5 
and 35 minutes post glucose injection, along with significantly elevated blood glucose at 
35 minutes when compared to littermate controls (p < 0.05, Figure 3.5A). To directly 
assess beta-cell function, isolated islets from male MIPβ1KO and control mice were 
incubated overnight and basal insulin levels were measured using an insulin ELISA. 
Basal insulin secretion in male MIPβ1KO islets was significantly lower with ~50% the 
amount of insulin compared to control islets (p < 0.001, Figure 3.5C). When male 
MIPβ1KO islets were subjected to an ex vivo GSIS test, a significant reduction of insulin 
secretion in response to glucose challenge was observed compared to control islets (p < 
0.05, Figure 3.5E). The impairment in proper blood glucose management during fasting 
and under high glucose loading conditions in female MIPβ1KO mice at 16 weeks post-
tamoxifen led to the subsequent analyses of insulin release in vivo and ex vivo using 
isolated islets. Female MIPβ1KO mice subjected to a GSIS test had similar levels of 
plasma insulin as controls (Figure 3.5B). Isolated islets of female MIPβ1KO also had no 
change in basal insulin secretion (Figure 3.5D), and no significant reduction during the 
ex vivo GSIS test was observed (Figure 3.5F). 
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Figure 3.5 In vivo and ex vivo GSIS analyses 
In vivo GSIS assay showing blood glucose and plasma insulin levels after 16-hour fast in A) male and B) 
female control and MIPβ1KO mice. Basal insulin secretion from isolated islet of C) male and D) female 
control and MIPβ1KO mice. Ex vivo insulin secretion in response to high glucose conditions in isolated 
islet of E) male and F) female control and MIPβ1KO mice.  Black bars: control, white bars: MIPβ1KO 
group. Data are expressed as mean ± SEM (n = 4-7/group). *p < 0.05; ***p < 0.001 vs. control group. 
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3.4 Reduction of insulin secretory molecules in MIPβ1KO 
mice 
An investigation into the molecules involved in exocytosis of insulin granules was 
conducted. A significant reduction in the mRNA of Snap25 (p < 0.05, Figure 3.6A) and 
Vamp2 (p < 0.01, Figure 3.6B) was observed in male MIPβ1KO islets at 8 weeks post-
tamoxifen compared to controls. Immunofluorescence staining showed a clear reduction 
in SNAP25 and VAMP2 in beta-cells in alignment with the reduction in mRNA in male 
MIPβ1KO mice (Figure 3.7A,B). Both Syntaxin 1A (Stx1a) and Syntaxin 3 (Stx3) mRNA 
in male MIPβ1KO islets was unchanged compared to control mice (Figure 3.6C,D). 
Immunofluorescence staining for Munc18 showed a reduction in the beta-cells of male 
MIPβ1KO mice (Figure 3.7C). Female MIPβ1KO mice at 16 weeks post-tamoxifen 
showed a similar trend with reductions of Snap25, Vamp2, Syntaxin1A and Syntaxin3 
mRNA, but it was not statistically different compared to controls (Figure 3.8A-D). 
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Figure 3.6 qRT-PCR analyses of insulin exocytosis machinery mRNA in 8 weeks post-
tamoxifen male MIPβ1KO mice 
Relative gene expression of control and male MIPβ1KO mice for A) Snap25, B) Vamp2, 
C) Syntaxin1A (Stx1a), and D) Syntaxin3 (Stx3). Black bars: control, white bars: MIPβ1KO 
group. Data are expressed as mean ± SEM (n = 3-4/group). *p < 0.05 vs. control. 
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Figure 3.7 Immunofluorescence staining for insulin exocytosis proteins in 8 weeks 
post-tamoxifen male MIPβ1KO mice 
Representative immunofluorescence staining images with separated fluorescent channels 
for A) Snap25, B) Vamp2, and C) Munc18 (green), with insulin (red) in control and 
MIPβ1KO mice. Nuclei were stained with DAPI (blue) (n=3/group). Scale bar: 25 μm. 
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Figure 3.8 qRT-PCR analysis for insulin exocytosis proteins in 16 weeks post-tamoxifen 
female MIPβ1KO mice 
Relative mRNA expression of control and female MIPβ1KO mice for A) Snap25, B) Vamp2, 
C) Syntaxin1A (Stx1a), and D) Syntaxin3 (Stx3). Black bars: control, white bars: MIPβ1KO 
group. Data are expressed as mean ± SEM (n = 3/group). 
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3.5 Reduced beta-cell mass in MIPβ1KO mice 
Morphological studies of male MIPβ1KO (8 weeks post-tamoxifen) and control 
pancreata showed that the overall architecture of the pancreas was unaltered and islets 
remained intact in tight clusters (Figure 3.9A). Morphometric analyses of islet density 
(islets per mm2) showed a significant reduction in male MIPβ1KO mice compared to the 
controls (p < 0.05, Figure 3.9B). When islets were grouped based on their size, it was 
found that there were significantly more small islets (501-2500 μm2), and less of the large 
islets (2501-10000 μm2) in the male MIPβ1KO pancreas (p < 0.05, Figure 3.9C). The 
decrease in size seen in large islets was clearly related to a significant decrease (~60%) in 
beta-cell mass in male MIPβ1KO mice (p < 0.05, Figure 3.9D), yet there was no 
accompanied reduction in alpha-cell mass (Figure 3.9E). Because a reduction in beta-cell 
mass was seen, insulin (Ins) mRNA was examined using isolated islets from male 
MIPβ1KO mice and was found to be significantly decreased compared to control islets (p 
< 0.05, Figure 3.9F). There was no change in the expression of glucagon (Gcg) mRNA 
in male MIPβ1KO mice (Figure 3.9G). Immunofluorescence staining was also used to 
examined E-cadherin (Figure 3.10A) and Glut2 (Figure 3.10B), proteins known to be 
important in maintaining beta-cell function and glucose-sensing, and no change was 
detected in male MIPβ1KO mice. 
Morphological examination of female MIPβ1KO mice 16 weeks post-tamoxifen and 
control pancreata showed relatively smaller islets (Figure 3.11A); however, quantitative 
assessment of islet number per mm2 of pancreas was not significantly altered in female 
MIPβ1KO mice (Figure 3.11B). When examining female MIPβ1KO islet size, there was 
a significant increase in very small islets (< 500 μm2), but larger islets did not display any 
clear reduction (p < 0.05, Figure 3.11C). Although islet density and size was not 
significantly impacted, there was a significant reduction in beta-cell mass (~50%), 
implying that there is either a reduction in beta-cell proliferation or increase in apoptosis 
in female MIPβ1KO mice compared to controls (p < 0.01, Figure 3.11D). Unlike that 
seen in male MIPβ1KO, female MIPβ1KO showed a significant reduction in alpha-cell 
mass (p < 0.05, Figure 3.11E). Both Ins and Gcg mRNA levels were reduced in isolated 
57 
 
islets of female MIPβ1KO and control mice, but significance was not reached due to high 
variability among the samples (Figure 3.11F,G).  
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Figure 3.9 Morphometric analyses of 8 weeks post-tamoxifen male MIPβ1KO mice 
A) Representative immunofluorescence images showing insulin+ staining (red) and DAPI (blue) in 
control (left) and MIPβ1KO (right) mice. Scale bar: 200 µm. B) Islet number, C) islet size, D) beta-
cell mass and E) alpha-cell mass of control and MIPβ1KO mice (n = 5-6/group). qRT-PCR analysis 
for F) Insulin and H) Glucagon mRNA of control and MIPβ1KO mice (n = 3-4/group). Black bars: 
control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM. *p < 0.05 vs. control group. 
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Figure 3.10 E-cadherin and Glut2 co-localization in 8 week post-tamoxifen male 
MIPβ1KO mice 
Representative immunofluorescence staining images for islets of control and MIPβ1KO 
mice for A) cell adhesion molecule e-cadherin (green) and insulin (red) and B) glucose-
sensing transporter Glut2 (green) and insulin (red). Nuclei were stained with DAPI (blue) 
(n = 3/group) Scale bar: 25 µm. 
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Figure 3.11 Morphometric analyses of 16 weeks post-tamoxifen female MIPβ1KO mice 
A) Representative immunofluorescence images showing insulin+ staining (red) and DAPI (blue) in 
control (left) and MIPβ1KO mice (right) mice. Scale bar: 200 µm. B) Islet number, C) islet size, D) 
beta-cell mass and E) alpha-cell mass of control and MIPβ1KO mice (n = 5/group). qRT-PCR analysis 
for F) Insulin and H) Glucagon mRNA of control and MIPβ1KO mice (n = 3/group). Black bars: 
control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM. *p < 0.05 vs. control group. 
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3.6 Reduction of Pdx-1 mRNA and protein levels in male 
MIPβ1KO mice  
Because of the significant impairment in glucose tolerance and insulin secretion in male 
MIPβ1KO mice 8 weeks post-tamoxifen, it was important to elucidate the underlying 
mechanism behind the dysfunction. Pdx-1 is an important regulator of insulin 
transcription (Ahlgren et al. 1998) and both mRNA and protein levels were significantly 
reduced in the β1KO model reported by Riopel (2011). The level of Pdx-1 mRNA in the 
islets of male MIPβ1KO mice was significantly reduced by ~40% when compared to 
control mice (p < 0.01, Figure 3.12A), along with a significant reduction in Pdx-1 
protein level as measured by western blot (p < 0.01, Figure 3.12B). Immunofluorescence 
staining for Pdx1 in beta-cells of male MIPβ1KO mice was consistently less intense than 
controls (Figure 3.12C). We further examined transcription factors Nkx6.1 (Figure 
3.13A), NK2 homeobox2 (Nkx2.2) (Figure 3.13B), Islet-1 (Isl-1) (Figure 3.13C) and v-
maf avian musculoaponeurotic fibrosarcoma homolog A (Mafa) (Figure 3.13D) using 
dual immunofluorescence staining or immunohistochemical staining, and found relatively 
similar staining intensities displayed between male MIPβ1KO mice and control mice. 
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Figure 3.12 Examination of Pdx-1 expression in 8 weeks post-tamoxifen male MIPβ1KO 
mice 
A) Pdx-1 mRNA expression and B) Pdx-1 protein levels in control and MIPβ1KO mice with a 
representative blot shown (n = 3-6/group). C) Representative immunofluorescence images for 
Pdx-1 (green), insulin (red) and DAPI (blue) in control and MIPβ1KO mice. Scale bar: 25 µm. 
Black bars; control, white bars; MIPβ1KO group. Data are expressed as mean ± SEM. ** p < 0.01 
vs. control. 
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Figure 3.13 Transcription factor expression in 8 week post-tamoxifen male 
MIPβ1KO mice 
Representative immunofluorescence images and quantification for A) Nkx6.1 (green) and 
insulin (red), B) Nkx2.2 (green) and insulin (red), C) Isl-1 (red) and insulin (green). D) 
Representative immunohistochemical staining for MafA (red) in control and MIPβ1KO 
mice. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± 
SEM (n = 2-5/group). Scale bar = 25 µm. 
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3.7 β1 integrin deficiency in beta-cells does not affect islet 
vasculature 
Immunofluorescence staining for PECAM and insulin showed no discernable differences 
in the vascularization of islets in 8 weeks post-tamoxifen male MIPβ1KO mice (Figure 
3.14A). Islet capillary area and diameter showed no significant changes relative to 
controls (Figure 3.14B,C). Just as with the male MIPβ1KO mice, female MIPβ1KO 
mice 16 weeks post-tamoxifen had no obvious changes in islet vasculature (Figure 
3.14D). Quantitative assessment of female MIPβ1KO islet capillary area and diameter 
also showed no changes compared to control mice (Figure 3.14E,F). These findings 
demonstrate that vasculature is unaltered in MIPβ1KO mice. 
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Figure 3.14 Measurement of islet vascularization in MIPβ1KO mice 
A) Representative immunofluorescence staining of PECAM (green), insulin (red) and 
DAPI (blue) in control and male MIPβ1KO mice. Scale bar: 25 µm. Quantification of 
blood vessel area (B) and density (C) in control and male MIPβ1KO mice. D) 
Representative immunofluorescence staining of PECAM (green), insulin (red), and DAPI 
(blue) in female control and MIPβ1KO mice. Scale bar: 25 µm. Blood vessel area (E) and 
density (F) quantification in female control and MIPβ1KO mice. Black bars: control, white 
bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 2-5/group). 
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3.8 Reduction of phosphorylated-FAK, ERK1/2, and Akt 
protein levels with altered cell proliferation pathways in male 
MIPβ1KO mice 
FAK and its downstream signalling molecules ERK1/2 and Akt have been shown to be 
important in beta-cell proliferation, survival, and function (Riopel et al. 2011, Feng et al. 
2015). In line with results reported by Riopel (2011) and Diaferia (2013) using the β1KO 
and RIPβ1KO models respectively, there was a significant reduction in p-FAKY397 (p < 
0.001, Figure 3.15A) and p-ERK1/2 (p < 0.05, Figure 3.15B) in male MIPβ1KO mice 8 
weeks post-tamoxifen compared to controls. A significant decrease in p-AktS473 was also 
observed in male MIPβ1KO mice (p < 0.05, Figure 3.15). Analysis of the proliferation 
marker cyclin D1 in isolated islets from male MIPβ1KO mice showed a significant 
reduction compared to control islets (p < 0.05, Figure 3.15D). The protein level of the 
apoptotic marker c-PARP was also significantly increased in male MIPβ1KO islets (p < 
0.05, Figure 3.15E). Immunofluorescence staining for the proliferative marker Ki67 in 
male MIPβ1KO islets was similar to that of controls (Figure 3.15G).  
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Figure 3.15 Cell signalling, proliferation, and apoptosis in 8 weeks post-tamoxifen male MIPβ1KO mice 
Western blot analyses for A) p-FAKY397, B) p-ERK1/2, and C) p-AktS473, with representative blots shown for 
control and MIPβ1KO mice. D) Cyclin D1 and E) c-PARP protein levels with representative blots from control 
and MIPβ1KO mice. F) Representative immunofluorescence staining for Ki67 (green), insulin (red) and DAPI 
(blue), and quantification of Ki67+ beta-cells for control and MIPβ1KO mice. Scale bar: 25 μm. Black bars: 
control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-11/group). *p < 0.05, ***p < 
0.001 vs control.  
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3.9 Expression of other integrin subunits in male MIPβ1KO 
mice 
The examination of other integrin subunits was conducted to see if there was any 
upregulation in a compensatory manner due to the knockdown of β1 integrin in male 
MIPβ1KO mice 8 weeks post-tamoxifen. qRT-PCR analysis of α3 integrin mRNA 
showed no change (Figure 3.16A), however qualitative assessment of 
immunofluorescence staining for the subunit in male MIPβ1KO mice showed an increase 
(Figure 3.17A). mRNA for α5 integrin was relatively unchanged (Figure 3.16B) and 
immunofluorescence staining showed co-localization to alpha-cells with no obvious 
differences compared to controls (Figure 3.17B). mRNA levels for α6 and αV integrins 
showed no change (Figure 3.16C,D), and there was no clear differences in 
immunofluorescence staining for these integrins in male MIPβ1KO islets compared to 
controls (Figure 3.17C,D).  
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Figure 3.16 qRT-PCR analyses for integrin alpha subunits in 8 weeks post-
tamoxifen male MIPβ1KO mice 
Relative mRNA expression for: A) α3 integrin, B) α5 integrin, C) α6 integrin, and 
D) αV integrin in control and male MIPβ1KO mice. Black bars: control, white bars: 
MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-4/group).  
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Figure 3.17 Immunofluorescence staining for integrin alpha subunits in 8 
weeks post-tamoxifen male MIPβ1KO mice 
Representative immunofluorescence images with separated fluorescence 
channels for A) α3 integrin, B) α5 integrin, C) α6 integrin, and D) αV integrin 
(green) with insulin (red) in control and male MIPβ1KO mice. Nuclei were 
stained with DAPI (blue) (n=3/group). Scale bar: 25 μm. 
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3.10 Glucose intolerance was maintained in aged MIPβ1KO 
mice 
To investigate whether MIPβ1KO mice could recover overtime as an adaptive response 
through increased expression of other integrins, aged MIPβ1KO mice at 25-35 weeks 
post-tamoxifen were examined. Aged male MIPβ1KO mice showed significantly 
elevated blood glucose after an overnight fast (p < 0.05, Figure 3.18A). Aged female 
MIPβ1KO mice also displayed relatively high fasting blood glucose levels, but there was 
no statistical significance compared to control mice (Figure 3.18B). Similar BW was 
observed in all aged groups (Figure 3.18C,D). IPGTT in aged male MIPβ1KO mice 
showed significantly elevated blood glucose levels at 60, 90 and 120 minutes after 
glucose injection with a significantly increased overall AUC when compared to control 
mice (p < 0.05-0.01, Figure 3.18E). An IPGTT in the aged female MIPβ1KO mice 
showed significantly elevated blood glucose levels at 30, 60, 90, and 120 minutes after 
glucose load (p < 0.05-0.01) along with a significantly increased AUC (p < 0.05 – 0.01, 
Figure 3.18F).   
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Figure 3.18 Metabolic analyses of aged MIPβ1KO mice 
Fasting blood glucose of aged A) male and B) female control and MIPβ1KO mice. Body weight 
for aged C) male and D) female control and MIPβ1KO mice. E) IPGTT analysis of control and 
aged male MIPβ1KO mice and the corresponding AUC. F) IPGTT analysis of control and aged 
female MIPβ1KO mice, with the corresponding AUC. Black bars: control, white bars: MIPβ1KO 
group. Data are expressed as mean ± SEM (n = 6-14/group). *p < 0.05, **p < 0.01 vs. control. 
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4 Chapter 4 - Discussion 
This study aimed to examine the role of β1 integrin in the beta-cells of adult mice using a 
beta-cell specific knockout of β1 integrin. Based on previous literature, I hypothesized 
that the MIPβ1KO mice would have impaired glucose tolerance and insulin secretion 
(through a reduction of SNARE proteins involved in insulin exocytosis), reduced beta-
cell mass, and a reduction in FAK/MAPK/ERK and PI3K/Akt activity. My key findings 
confirmed my hypothesis.  
4.1 Knockdown of β1 integrin in MIPβ1KO mice 
Tamoxifen was given I.P. at 4 mg/20g BW for 3 consecutive days to produce 
MIPβ1KO mice. This regimen was adapted from the dosage given in Furuyama et al. 
(2011), where 4 mg/ 20 g BW was given I.P. for 5 days every 48 hours. This dosage 
demonstrated sufficient CreER activation as indicated by x-gal staining, along with no 
apparent organ damage and no abnormalities within plasma samples (Furuyama et al. 
2011). Consecutive dosages at such a high concentration of tamoxifen has not be used in 
any publications and it was observed that some male, and many female mice from both 
control and KO groups, became ill after the second and third round of tamoxifen 
administration. Various reports have been published regarding the potential toxicity of 
tamoxifen (Denk et al. 2015, Huh et al. 2012, Bersell et al. 2013, Phillips DH 2011). It is 
also possible that the surviving mice were not all receiving a consistent I.P. dose of 
tamoxifen, and that those receiving the higher end of the dose are the ones that did not 
survive. One potential factor for variability in tamoxifen dosages are human error, such 
as leakage of the corn oil-based tamoxifen solution from the injection site, as well as the 
potential for injecting into areas other than the peritoneal cavity, such as the abdomen, 
spleen, or even the pancreas itself.  
It was apparent that a sufficient knockdown was achieved in male MIPβ1KO mice, as 
verified by western blot (~40% knockdown), qRT-PCR (~60% knockdown), and an 
observable difference in immunofluorescence staining intensity of β1 integrin. These 
values are comparable to those achieved in Riopel (2011, 2013), and despite a larger 
dosage of tamoxifen used in this study (4 mg/ 20 g BW for 3 consecutive days compared 
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to 1mg tamoxifen for 5 consecutive days), it did not lead to any clear differences in 
knockdown between the models. However, female mice responded differently to the 
specified tamoxifen dose, which requires further elaboration. Although mRNA levels 
showed a slight decrease in β1 integrin along with a clear reduction of β1 integrin in 
insulin positive cells as assessed by immunofluorescence staining, isolated islet protein 
showed no change compared to controls. Riopel (2011, 2013) also noted that female mice 
did not display as drastic a phenotype as male mice. Female MIPβ1KO mice showed no 
significant decreases in glucose tolerance until 16 weeks of age, demonstrating there is 
some underlying protective factor in female mice that becomes lessened with age. Along 
this rationale of thinking, it is possible that the less overt phenotype observed in female 
mice throughout this study is primarily due to differences in the degree of β1 knockdown 
due to dosage, age, or potentially through the protective effect of estrogen that has been 
observed in beta-cells of streptozotocin and alloxan treated female mice (Kilic et al. 
2014, Le et al. 2006). It was apparent that the tamoxifen dosage used was sufficient to 
induce a significant knockdown of β1 integrin in the pancreatic beta-cells of male 
MIPβ1KO mice, and although there are no previous studies reporting gender differences 
in tamoxifen sensitivity (see Feil et al. 2009 for a review), it was clear that induction of 
the β1 integrin knockdown did not increase with the dosage of tamoxifen given. The 
higher dosage used in this study as opposed to that used in Riopel (2011, 2013) was not 
sufficient to induce a significant reduction of β1 integrin in female MIPβ1KO mice. 
4.2 Do MIPβ1KO mice have impaired glucose tolerance and 
insulin secretion?  
Unlike the previous study utilizing a global β1KO model (Riopel 2011, 2013), there was 
no difference in body weight, pancreatic weight and macrostructure between MIPβ1KO 
and control mice.  Although fasting blood glucose levels were only significantly elevated 
in female MIPβ1KO mice and not males, both genders showed significantly elevated 
blood glucose levels during an IPGTT. Even though these findings are not in alignment 
with data published by Diaferia (2013), it is important to note that the knockout of β1 
integrin in our study was conducted in adult mice, without any time for compensation by 
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other integrins during embryonic and postnatal (p0-p21) development. The findings of 
glucose intolerance observed are more in agreement with published studies by Riopel 
(2011) and Cai (2012), where either knockdown of β1 integrin in adults or knockout of 
FAK from conception leads to impaired glucose tolerance in adult life. Because there was 
no change in insulin tolerance in MIPβ1KO mice, the prolonged elevation in blood 
glucose levels in both male and female mice are either indicative of a defect in insulin 
secretion, a reduction in beta-cell mass, or both. As such, an in vivo GSIS assay was 
conducted and plasma insulin levels were examined. Male MIPβ1KO mice had 
significantly reduced plasma insulin levels after I.P glucose injection, indicating an 
overall decrease in total insulin production. However, female mice did not display a 
similar trend. To further assess if it was beta-cell dysfunction or some other underlying 
mechanism leading to reduced plasma insulin after an administered glucose load, islets 
were subjected to an ex vivo GSIS assay. Just as in Cai (2012), isolated islets had reduced 
insulin secretion in response to an increased concentration of glucose in the media. Basal 
insulin secretion levels were also reduced in male MIPβ1KO indicating some impairment 
normal levels of insulin secretion. To understand what was leading to this impairment, an 
examination of exocytotic proteins involved in insulin secretion was conducted. 
4.3 Are insulin secretory molecules altered in MIPβ1KO 
mice? 
It was clear in male MIPβ1KO mice that there was reduced VAMP-2 and SNAP-25 at 
both the mRNA and protein level. This deficiency leads to impaired insulin vesicle 
docking, as the interaction between VAMP-2 on the membrane of vesicles and SNAP-25 
on the plasma membrane is a requirement for proper vesicle fusion (Fasshauer 2002). Just 
as studies have shown that focal adhesion remodelling is required for proper glucose 
stimulated insulin secretion through FAK-paxillin interactions, which subsequently affect 
SNAP-25 levels (Rondas et al.2011, Cai et al. 2012), the β1 integrin knockout in beta-
cells of adult mice seems to have a similar effect. Although there were no changes in 
Stx1A and Stx3, a reduction in Munc18 protein was found. Munc18 is important in 
stabilizing the SNARE complex at the plasma membrane, mainly through interactions 
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with Stx1A (Thurmond 2013). No significant changes were observed in female 
MIPβ1KO mRNA levels of Snap25, Vamp2, Stx1A, and Stx3. The lack of a significant 
finding in insulin exocytotic proteins could potentially account for the indiscernible 
differences seen in glucose stimulated insulin secretion in female MIPβ1KO mice. These 
observations show that β1 integrin is required for maintenance of normal physiological 
levels of insulin exocytotic machinery that are pivotal in maintaining normoglycemic 
levels.     
4.4 Is β1 integrin required for proper islet morphology?  
Even though there was a defect in insulin secretion in MIPβ1KO mice, it was important 
to determine the changes of islet morphology and beta-cell mass. Both male and female 
MIPβ1KO mice, showed a decrease in beta-cell mass. This finding is in agreement with 
previous literature that sees a decrease in beta-cell proliferation when integrin is knocked 
out in beta-cells from conception (Diaferia et al. 2013), or knocked down globally in all 
col1a2 producing cells in adult mice (Riopel et al. 2011). In addition, when FAK, a key 
component in outside-in signalling of integrins is knocked down in beta-cells from 
conception a similar reduction in beta-cell mass is observed (Cai et al. 2012). To account 
for the reduction in beta-cell mass, cell cycle progression and apoptosis were examined. 
Akin to our previous publication (Riopel et al. 2011), a significant reduction in cyclin D1 
was observed along with an increase in c-PARP in male MIPβ1KO mice, whereas 
females did not show significant changes in these markers, presumably from the 
protective effect of estrogen as mentioned previously. Despite only seeing a significant 
change in proliferation and apoptotic markers in male MIPβ1KO mice, this is most likely 
the cause for the decrease in beta-cell mass of female MIPβ1KO mice as well.  
 
An interesting observation in the MIPβ1KO mice was a trend towards a decrease in 
alpha-cell mass in male mice, along with a significant reduction in female mice. In 
models of diet induced diabetes like the Goto-Kakizaki rat (Movassat et al. 1997) alpha-
cell mass can be decreased when beta-cells are reduced. The defect in normal alpha-cell 
mass is attributed to abnormal islet-architecture from the distinct reduction in beta-cell 
population, which subsequently impacts cell-to-cell contacts within the islet, along with 
87 
 
reduced nutrient secretion and protein secretion important in eliciting normal ECM 
development in and around the islets. 
 
With the overall decrease in beta-cell mass and changes in alpha-cell mass of MIPβ1KO 
mice, an overall examination of islet density was conducted. Male MIPβ1KO mice had 
fewer islets overall, which coincided with fewer medium (<501-2500µm2) and large 
(<2501-10000µm2) islets, and is similar to findings in Diaferia (2013).  Female 
MIPβ1KO mice, however, had an increase in small islets (<500 µm2) despite a trend 
towards decreased islet density. This increase in smaller islets, which was not seen in the 
males, clearly resulted in a greater number of islets per mm2 compared to their male 
counterparts. Despite these differences, it was clear that MIPβ1KO mice have altered islet 
morphology compared to their control littermates. 
 
One aspect that remained to be examined was that of transcription factors required for 
proper beta-cell differentiation and function. Both Pdx-1 and Nkx6.1 were reduced in the 
β1KO model used in Riopel (2011) and have been shown to be important in beta-cell 
differentiation and proper maintenance and function in adult mice (McKinnon & 
Docherty 2011, Taylor et al. 2013).  In the present study, male MIPβ1KO mice had a 
marked decrease in Pdx-1 mRNA and protein as assessed by qRT-PCR and western blot. 
However, there was no decrease in the number of Pdx-1+ cells beta-cells. This finding is 
in contrast to that of Diaferia (2013), where no change in Pdx-1 protein was observed. 
This could be due to the knockout of β1 integrin at conception rather than in adulthood, 
giving beta-cells time to engage compensatory mechanisms that account for the lack of 
β1 integrin and maintain normal expression levels of this transcription factor. Reduced 
Pdx-1 in male MIPβ1KO mice could be one factor that is responsible for the glucose 
intolerance, decreased insulin levels, and decreased beta-cell mass that was observed in 
them. Unlike the β1KO model (Riopel et al. 2011, Riopel et al. 2013), there was no 
change in Nkx6.1 protein in MIPβ1KO mice. The changes in ECM composition observed 
in these previous studies, mainly a decrease in collagen fibers and connective tissue 
surrounding the islets, is a potential reason why there was a decrease in Nkx6.1 as well. 
The shift in ECM composition created a drastically different environment for the beta-
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cells to reside, and subsequently may be the reason why Nkx6.1 was decreased in β1KO 
and not RIPβ1KO or MIPβ1KO mice.  
4.5 Vasculature in the islets of MIPβ1KO mice 
Previous studies have shown that endothelial cells are required for proper deposition of 
the basement membrane, which in turn leads β1 integrin to promote beta-cell 
proliferation and insulin gene expression (Nikolova, 2006). Additionally, adequate 
vasculature is required for beta-cells to sense changes in blood glucose as well as provide 
a pathway for insulin to be released and distributed throughout the body (Brissova, 2006). 
It has been established that PaSCs, which are myofibroblast-like cells, can promote 
endothelial cell proliferation via secretion of vascular endothelial growth factor (VEGF) 
(McCarroll et al. 2014). Based on these findings it is not surprising that vasculature was 
reduced in the β1KO model used by Riopel et al. (2011), in which both PaSCs and 
pericytes, cells that adhere and aid in vasculature formation in addition to ECM 
deposition, were both lacking β1 integrin. Unlike this previous study where β1 integrin 
was lacking in PaSCs and pericytes, our beta-cell specific knockout did not lead to a 
significant impairment in endothelial cell number and overall vascularization of islets. 
Although, these were only qualitative studies. Despite beta-cells having a role in VEGF 
secretion and recruitment of endothelial cells (Nikolova et al. 2006), having normal β1 
integrin levels in PaSCs and pericytes seems to overcome any deficit in VEGF-A 
secretion, allowing for normal islet vascularization in MIPβ1KO mice. 
4.6 Signalling in MIPβ1KO mice 
The role of β1 integrin in regulating FAK and its downstream signalling molecules has 
been examined in a multitude of different cell types, including pancreatic beta-cells and 
beta-like cells (e.g., INS-1 cells). Our study found a significant reduction in the 
phosphorylation of FAKY397, and this is in alignment with several studies, all of which 
show that β1 integrin is one regulator of phosphorylating FAK at tyrosine 397 (Hammer 
et al. 2004, Kaido et al. 2004, Wang et al. 2005, Krishnamurthy et al. 2008, Saleem et al. 
2009, Riopel et al. 2011). FAK is responsible for regulating a multitude of downstream 
signalling molecules, one of which is ERK1/2, which has shown to be important in 
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maintaining function and survival in beta-cells and beta-like cells in vitro (Hammer et al. 
2004, Krishnamurthy et al. 2008, Saleem et al. 2009) and beta-cells in vivo (Riopel et al. 
2011, Cai et al. 2012). A significant reduction in phosphorylation of ERK1/2 was also 
found in the MIPβ1KO mice. Activation of ERK1/2 has been shown to play a role in 
beta-cell survival and Pdx-1 regulation (Hammer et al. 2004, Saleem et al. 2009, 
Krishnamurty et al. 2008, Riopel et al 2011, Dioum et al. 2010), as well as regulating 
glucose-stimulated insulin secretion mediated by actin remodelling (Tomas et al. 2006, 
Rondas et al. 2011). One-point worth noting is the fact that the RIPβ1KO model (Diaferia 
et al. 2013) had a reduction in ERK1/2 but showed no overt phenotype, this is most likely 
attributed to compensation by other integrins as mentioned throughout this discussion, 
which has led to the less overt phenotype in this mouse model compared to MIPβ1KO 
model, where the knockout was induced in adults and not from conception. An 
interesting finding that was not observed in the β1KO mouse model (Riopel et al. 2011) 
was a decrease in pAktS473, which was also reduced in the RIPβ1KO model (Diaferia et 
al. 2013) and the beta-cell specific FAK knockdown model (Cai et al. 2012). Research 
has been published showing that FAK and Src which are downstream of integrins play a 
role in activation of p85 subunit of PI3K that leads to AktS473 activation (Xia et al. 2004). 
Akt has been shown to play a significant role in cell survival by mediated apoptotic 
proteins such as Bcl2 while also preventing activation of caspase-9 (Song et al. 2005). As 
such, this pathway could also be contributing to the reduced survival of beta-cells 
observed in the MIPβ1KO mouse model.  
4.7 Aged MIPβ1KO mice and a lack of functional 
compensation by other integrins 
One of the more interesting aspects of integrin signalling is the ability to have 
compensatory outside-in signalling through increased expression of other integrin 
subunits when one is impaired (Diaferia et al. 2013). The low proliferative rate of beta-
cells in mammals should lead to maintenance of the β1 integrin knockdown in the 
majority of the beta-cell population, providing ample opportunity for compensation by 
other integrins within affected beta-cells (Kushner 2013). It has been shown that β3 and 
β5 integrins can maintain and enhance cellular differentiation when β1 integrin is either 
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functionally blocked or deleted at the gene level (Brunetta 2012, Guan 2001, Hirsch 
1998, Jeanes 2012, Retta 1998). Diaferia (2013) reported an up-regulation of vitronectin 
and the laminin-5 β-chain in their RIPβ1KO model, which are known ECM ligands of the 
αvβ3 and α6β4 integrins, respectively. In the present study, the α3 integrin subunit, 
known to form a heterodimer with β1 integrin, showed no change in mRNA, whereas 
immunofluorescence staining showed a qualitative increase in this protein indicating a 
possible compensation through upregulation of α3 integrin. Interestingly the mRNA of αv 
and α6 was relatively low, but no difference at the protein level as assessed by 
immunofluorescence staining was observed. These two integrins are associated with 
other β subunits, indicating that loss of β1 integrin did not increase other integrin 
expression such as α6β4 and αV associated β subunits. Since there is no significant 
increase of other αβ integrin expression in MIPβ1KO islets, mice were aged to see if they 
could recover from the glucose intolerant phenotypes observed at their respective time 
points. It was clear that the initial knockout of β1 integrin at 3-4 weeks of age was 
significant enough to impact beta-cell function long-term, since the aged mice still 
displayed glucose intolerance, more-so than they did 8 and 16 weeks post-tamoxifen. 
Age, in addition to the initial knockdown of β1 integrin, could therefore play a factor in 
this increase in impaired glucose metabolism observed in the aged mice due to the lack of 
compensation through other integrins in the beta-cells of MIPβ1KO mice. 
4.8 Limitations of the study 
One of the limitations in using a mouse model is that it does not directly translate to 
humans. There are distinct differences in ECM composition, islet organization, diet and 
living conditions that all directly influence the outcomes that are observed.  Regarding 
ECM composition, it has been shown that mice and humans, for example, have overlap in 
terms of laminin isoforms that they interact with (such as laminin-8), yet murine islets 
express laminin-10 as well, which is absent in human islets (Otonkoski et al. 2008). Such 
small variations in ECM composition might not seem like much, but when one compares 
the 804G matrix (rich in laminin-5) to commercially available Matrigel (containing 
Laminin-1), islet cells will differentiate in Matrigel to pancreatic ductal cells, whereas the 
804G matrix does not have this effect (Gao et al. 2003, Bonner-Weir et al. 2000). 
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Although β1 integrin has high variability in terms of its ability to interact with a plethora 
of ECM ligands through the 11 different α subunits it associates with, the overlap of other 
integrins and differences in ECM composition and integrin expression in murine 
compared to human islets and beta-cells should not be dismissed.  
One fundamental issue with the RIP mouse line used to drive Cre recombinase was 
ectopic expression found in the hypothalamus, potentially leading to differences in 
metabolism and energy maintenance (Wicksteed et al. 2010). Despite initial reports 
stating that the MIP construct was beta-cell specific (Tamarina et al. 2014), a study using 
more sensitive measures has detected the presence of MIP in the hypothalamus as well 
(Wang et al. 2014). Therefore, utilizing MIP to induce beta-cell gene knockouts face the 
same confounding variables as the RIP construct.  
Another issue with using transgenic mouse lines is the methodology used to incorporate 
our transgene of interest. In the case of many transgenic mice, the human growth 
hormone (hGH) is included in order to increase transgene expression (Brinster et al. 
1988, Palmiter et al. 1983, Palmiter et al. 1991). It was originally thought that the 
transgene was not transcribed and translated into growth hormone, but recent studies 
have shown its presence in beta-cells (Brouwers et al. 2014). The RIP-Pdx1late mouse line 
have lower blood glucose, increased beta-cell mass and are resistant towards STZ-
induced beta-cell death due to binding of hGH to prolactin receptor which stimulates 
serotonin production within beta-cells (Baan et al. 2015). Within the present study, we 
incorporated both MIP+/β1+/+ and MIP-/β1fl/fl into the control group, but when strictly 
comparing MIP+/β1+/+ mice to MIP+/ β1fl/fl mice, we still found that the knockdown mice 
were glucose intolerant at both the adult and aged time points. Despite this finding, the 
presence of the hGH construct should not be ignored when assessing MIPβ1KO mice and 
how the findings might accurately translate to human physiology. 
One final limitation worth noting is that the decrease in β1 integrin was roughly ~40% in 
beta-cells of MIPβ1KO mice compared to controls, therefore being only a partial 
knockdown. Because the beta-cells still have more than 50% of remaining β1 integrin 
levels, the effect of a total knockdown in adult mouse beta-cells remains unknown. 
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Additionally, with the corresponding amount of β1 integrin protein present, it is possible 
this prevented any significant upregulation of other integrins in an attempt to compensate, 
unlike the compensation that was seen in the RIPβ1KO mouse line from conception. 
Overall, the effects of complete β1 integrin knockdown in adult murine beta-cells 
remains to be determined. 
4.9 Conclusions and future directions 
This study demonstrates that subnormal physiological levels of β1 integrin in the beta-
cells of murine islets leads to pathological distress, more so in males then in females as 
previously described. The mice are unable to overcome the deficit in β1 integrin and 
results in impaired glucose tolerance and insulin secretory machinery. The reduction in 
β1 integrin leads to reduced beta-cell mass and altered islet size and density, along with 
increased apoptosis and decreased proliferation. The signalling pathways downstream of 
β1 integrin (FAK/ ERK1/2 and Akt) are also affected by reduced β1 integrin levels, 
leading to the observed phenotype. A summary of the key findings of this study is 
presented in Figure 4.1. 
The overall significance of this study stems from islet transplantation as a method to treat 
T1D. One of the fundamental issues is a lack of donor tissue, so finding optimum 
conditions to reproduce native environments is of utmost importance in order to maintain 
survivability of isolated islets, and perhaps in the future, to maintain and reproduce stem-
cell derived beta-like cells. One promising avenue is the concept of encapsulating islets, 
or even just beta-cells themselves, to prevent an autoimmune attack (Vegas et al. 2016). 
However, ensuring survival of these cells requires not only protection from the immune 
system, but a sustainable environment as well. The importance of the ECM has been well 
documented throughout this dissertation, and elucidating the role of integrin receptors 
and their interaction with ECM ligands is paramount in constructing a long-term cure for 
treatment of T1D.  
One future avenue of research utilizing the MIPβ1KO model would be to assess what 
happens during murine embryonic development. Inducing a knockdown of β1 integrin 
during both the second and third phases of development will not only provide insight into 
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its role during the aforementioned periods, but allowing these mice to age to adults would 
allow time to see if the organisms can compensate for this deficit. By determining 
alternative pathways or proteins that can aid in maintaining the functional state of beta-
cells, or determining what is absolutely required as the animals progress from embryonic 
to adults, one can further the knowledge required for finding ways to treat diabetes. 
Finally, finding a relationship between β1 integrin and proteins involved in the SNARE 
complex that is essential for not only insulin secretion, but docking of integrins to the 
plasma membrane is a novel area of study. This study has shown that a reduction in β1 
integrin affects SNAP25 and Munc18 mRNA and protein, which is a novel finding. 
Studies examining this relationship might provide future ideas for ways to enhance beta-
cell insulin secretion through ECM or integrin interactions. 
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Figure 4.1 Impact of the MIPβ1KO model in male mice 
The tamoxifen induced beta-cell specific knockout of β1 integrin lead to a multitude of 
impairments in male MIPβ1KO mice. A reduction in the SNARE complex proteins 
Snap25, Vamp-2 and Munc18-1 was observed, however the mechanisms that lead to this 
reduction remain to be seen. A reduction in phosphorylated (P) FAK, ERK1/2 and Akt 
was also observed, and these proteins have been shown to play a role in mediating beta-
cell proliferation, survival, and function.  
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    Appendix A: Animal use protocol 
2008-038-04::6:
AUP Number: 2008-038-04
AUP Title: Pancreatic Beta Cell Development: The Role of the c-Kit and Integrin Receptors
Yearly Renewal Date: 11/01/2014
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2008-038-04 has been approved,
and will be approved for one year following the above review date.
This AUP number must be indicated when ordering animals for this project.
Animals for other projects may not be ordered under this AUP number.
Purchases of animals other than through this system must be cleared through the ACVS ofﬁce.
Health certiﬁcates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this
protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional
safety standards and have received all necessary approvals. Please consult directly with your
institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
Subject:
To:
Cc:
Date:
From:
eSirius Notiﬁcation - Annual Protocol Renewal
APPROVED by the AUS 2008-038-04::6
11/28/14 11:51 AM
esiriusadmin@uwo.ca, (eSiriusWebServer) 
https://iwc.uwo.ca/iwc_static/layout/shell.html?lang=en&2-4.0...
1 of 1 2014-11-28, 12:05 PM
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Permit Summary
Permit # BIO-LHRI-0046
Wang, Rennian 
Department Physiology
Phone 5196858500 Ext. 55098     
Email rwang@uwo.ca
Approval Date Apr 25, 2014 Expiration Date Apr 24, 2017
BioSafety Officer's Signature
Permit Holder
Classification 2       
Building Room Room Area Lab Phone Ext. Level
organs and tissues (unpreserved), organs and tissues (preserved)
Human (primary), fetal pancreas and duodenum, Rodent (primary), mouse pancreatic islets, human (established), PANC-1, HEK293, 
Rodent (established), INS-1, AR42J
B6 mice
Streptozotocin, Tamoxifen
Organism
Cell
Human
GMO
Animals
Toxin
Plant/Insect
Gene Therapy
Other OFF CAMPUS 2
Page 1 of 2April-28-14
Appendix B: Classification II laboratory approval form 
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University of Western Ontario
Permit Summary
Permit # BIO-LHRI-0046
Wang, Rennian 
Department Physiology
Phone 5196858500 Ext. 55098     
Email rwang@uwo.ca
Approval Date Apr 25, 2014 Expiration Date Apr 24, 2017
BioSafety Officer's Signature
Permit Holder
Classification 2       
Permit Conditions
I accept the above responsibilities as a Internal Permit Holder and I am accountable for following UWO BioSafety Guidelines and Procedures Manual for 
Containment Level 1 and 2 Laboratories.
Permit Holder Name Signed Date
1 INTERNAL PERMIT HOLDER RESPONSIBILITIES
Comply with UWO BioSafety Safety Policies and Standard Operating Procedures.  Ensure that the Health Canada Biosafety Guidelines, relevant 
regulations and safe laboratory practices are followed.
1.1 Receive adequate biosafety training from the institution. Permit Holders are responsible for the provision of specific training and instruction in 
biohazard agent handling that is necessary for the safe use of this material in their own laboratories. Supervisors must ensure that workers 
understand the health and safety hazards of the work or task (due diligence).
1.2 Ensure that the UWO Biosafety Manual is available to all lab personnel under the permit.
1.3 Report incidents of loss or theft of any biohazardous material immediately to the Biosafety Coordinator;
2 WORKER RESPONSIBILITIES
Be familiar with the UWO Biosafety Manual, attend all required safety training sessions and obey all safety regulations required by the UWO 
Biosafety Committee.
2.1 Report to the Permit Holder any incident involving known or suspected exposure, personal contamination or a spill involving a biohazardous agent.
Page 2 of 2April-28-14
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